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Abstract

IMMUNOTHERAPY OF CANCER: REPROGRAMMING TUMOR/IMMUNE
CELLULAR CROSSTALK TO IMPROVE ANTI-TUMOR EFFICACY

By Kyle Kristopher Payne, PhD
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2015

Director: Masoud H. Manjili, DVM, PhD
Associate Professor, Department of Microbiology and Immunology
School of Medicine

Immunotherapy of cancer has been shown to be promising in prolonging patient survival.
However, complete elimination of cancer and life-long relapse-free survival remain to be major
challenge for anti-cancer therapeutics. We have previously reported that ex vivo reprogramming
of tumor-sensitized immune cells by bryostatin 1/ionomycin (B/I) and the gamma-chain (γ-c)
cytokines IL-2, IL-7, and IL-15 resulted in the generation of memory T cells as well as CD25+
NKT cells and CD25+ NK cells. Adoptive cellular therapy (ACT) utilizing these reprogrammed
xvi

immune cells protected FVBN202 mice from tumor challenge, and overcame the suppressive
functions of myeloid-derived suppressor cells (MDSCs). We then demonstrated that the presence
of CD25+ NKT cells was required for anti-tumor efficacy of T cells as well as their resistance to
MDSCs. Similar results were obtained by reprogramming of peripheral blood mononuclear cells
(PBMC) from patients with early stage breast cancer, demonstrating that an increased frequency
of CD25+ NKT cells in reprogrammed immune cells was associated with modulation of MDSCs
to CD11b-HLA-DR+ immune stimulatory cells. Here, we tested the efficacy of immunotherapy
in a therapeutic setting against established primary breast cancer (Chapter One), experimental
metastatic breast cancer (Chapter Three) as well as against minimal residual disease (MRD) in
patients with multiple myeloma (Chapter Two). We evaluated the ability of reprogrammed
immune cells, including CD25+ NKT cells, to convert MDSCs to myeloid immune stimulatory
cells, in vivo; this resulted in the identification and characterization of a novel antigen presenting
cell (APC). These novel immune stimulatory cells differed from conventional APCs, including
dendritic cells (DCs) and macrophages. We have also demonstrated that enhancing
immunogenicity of mammary tumors by treatment with Decitabine (Dec) along with overcoming
MDSCs by utilizing reprogrammed T cells and NKT cells in ACT prolongs survival of animals,
but fails to eliminate the tumor. However, targeting cancer during a setting of MRD, when tumor
cells are dormant, results in objective responses as evidenced in our multiple myeloma studies.
This suggests that targeting breast cancer with immunotherapy following conventional therapies,
in a setting of residual disease when tumor cells are dormant, may be effective in eliminating
such residual cells or maintaining dormancy and extending time-to-relapse for breast cancer
patients.

xvii

PREFACE
Despite tumor immune surveillance, individuals with an intact immune system still develop
cancer. This is due to escape mechanisms developed by tumors under pressure from the host’s
immune system. Therefore, modifying tumor cells and reprogramming tumor-sensitized immune
cells may establish a novel crosstalk between tumor cells and cells of the immune system which
could lead to tumor rejection. The use of demethylating drugs such as Azacitidine (Aza) or Dec
can induce the expression of highly immunogenic cancer testis antigen (CTAs) in the tumor,
thereby increasing the immunogenicity of tumor cells and rendering them more vulnerable to
immune recognition and attack. We have also established an antigen-free ex vivo protocol for
reprogramming and expansion of tumor-sensitized immune cells by using bryostatin
1/ionomycin (B/I) and common gamma chain cytokines, IL-2, IL-7, and IL-15. Such
reprogrammed immune cells consisted mainly of memory T cells and CD25+ NKT cells, which
overcame MDSC suppression. Previous work demonstrated that ACT utilizing reprogrammed
immune cells protected animals from primary tumor challenge. Here, we sought to determine the
therapeutic efficacy of ACT against established primary breast cancer. In Chapter One, we
evaluated ACT with or without Dec against established primary mammary carcinoma. This
strategy failed to eliminate established tumors. In Chapter Two, we participated in a Phase II
randomized clinical trial using Aza combined with an immunomodulator Revlimid (Rev) and
ACT in patients with multiple myeloma who harbored MRD. This strategy was effective in
generating responses against multiple myeloma. In Chapter Three, we tested the therapeutic
efficacy of ACT with or without Dec against experimental metastatic mammary carcinoma.
These studies identified novel APCs, as well as chemotherapy-induced dormant tumor cells that
were sensitive to immunotherapy.
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Chapter One
Introduction
The role of the immune system in maintaining equilibrium or eliminating neoplastic cells has
become appreciated within the last four decades. Anti-tumor immune surveillance is supported
by observations of spontaneous tumor regression associated with anti-tumor immune function
(1), as well as the observation of a higher incidence of virally induced cancers and a worse
prognosis for other cancers in immunocompromised or immunodeficient patients (2, 3). Such
observations have incited the development of immune-based therapies for use against cancer in
order to harness naturally occurring anti-tumor immune response.

Status of current cancer therapeutics
Despite advances in conventional cytotoxic therapies of early-stage breast cancer (4, 5) there
remains no therapeutic strategy that can ensure relapse-free survival. Furthermore, studies have
shown that 20% of clinically disease-free early-stage breast cancer patients relapse within 10
years after conventional therapies (6); indeed, most cancer-related deaths within the United
States are attributed to relapse (7). Thus, there is an urgent need to develop more effective
therapies to overcome breast cancer relapse and to treat the advanced stages of the disease. To
this end, immunotherapy emerges as a promising strategy for the prevention of tumor relapse,
when combined with conventional therapies.
Thus far, advances in the immunotherapy of cancer have also been met with a number of
setbacks. Several vaccination strategies used against breast cancer have been successfully
employed to induce tumor-specific CD8+ and CD4+ T-cell responses; however, such
1

immunological responses have rarely been potent enough to achieve objective results (8-10).
Additionally, it has been demonstrated by several groups that adoptive cellular therapy (ACT)
directed against highly immunogenic melanoma-associated antigens results in objective
responses in animal models as well as in some melanoma patients (11, 12). ACT has also been
tested against breast cancer both in preclinical and clinical studies (13, 14); however, unlike
melanoma, ACT has not produced promising results in breast cancer patients and has only
displayed effectiveness in animal models in prophylactic settings (15, 16), rather than against
well-established, vascularized tumors. Such failure has been attributed, in part, to (i) the lack of a
robust antitumor immune response as a result of the expression of weakly immunogenic tumor
antigens coupled with the presence of low frequency and low affinity T cells and (ii) the
suppression of antitumor immune responses though the activity of immunosuppressive
mechanisms. Indeed, distant recurrence of breast cancer may occur even in the presence of
tumor-specific immune responses. The ability to overcome these barriers will likely improve the
efficacy of immunotherapy directed against cancer.

Immune suppression in the tumor microenvironment
The immunosuppressive tumor microenvironment (TME) has come to be appreciated as a major
facilitator in the progression of solid tumors. It is now clear that the escape of malignant cells
from immune destruction is due in part to immunosuppressive mechanisms within the TME, as
reviewed by Hanahan and Coussens (17). The expression of immunoregulatory molecules, such
as cytotoxic T lymphocyte associated protein 4 (CTLA-4) and programmed cell death protein 1
(PD-1) as well as the ectoenzyme, CD73, inhibits the proliferation and function of conventional
T cells with anti-tumor activity (18, 19). Furthermore, immunosuppressive cells such as
2

alternatively activated M2 macrophages, type II NK cells, and regulatory T cells have been also
been demonstrated to antagonize tumor immunosurveillance (20-24). Results from clinical
studies of

breast cancer patients indicate that another critical regulator of tumor

immunosurveillance, the myeloid-derived suppressor cell (MDSC), was found to be the most
abundant type of suppressor cell (25, 26) and thus represent a major hurdle in overcoming
antitumor immune suppression. MDSCs play a major role in the suppression of anti-tumor
immune responses as the failure of endogenous anti-tumor immune responses results, in part,
from the increased activity of these cells (27-29). MDSCs consist of immature cells of myeloid
origin that exert suppression of T cells via modulation of the local T-cell environment, direct
cell-to-cell contact, as well as by their ability to generate inducible Tregs (15, 30-33). These cells
have been found in tumor-bearing mice as well as cancer patients and have been shown to
possess multiple mechanisms to suppress the antitumor immune response (34, 35). Such
responses include disrupting T cell receptor (TcR) antigen recognition and T-cell mediated
interferon gamma (IFN- ) production (36, 37), depletion of essential amino acids within the
tumor microenvironment (38), and overproduction of reactive oxygen species (ROS) (39).
Murine MDSCs are defined as coexpressing Gr-1 and CD11b, with two subsets commonly being
described: granulocytic (CD11b+Ly-6G+Ly-6C-) and monocytic (CD11b+Ly-6G-Ly-6C+) (40).
Human MDSCs, on the other hand, have been difficult to identify as initial studies revealed that
these cells express varied phenotypes and suppressive patterns (34). It is now regarded, however,
that human MDSCs fall into two main subsets: a monocytic population characterized by
expression of CD14 and a granulocytic population characterized by CD15 expression; both
subtypes have been reported to express the common myeloid markers CD11b and CD33, with
minimal expression of myeloid maturation markers such as HLA-DR (41). The accumulation of
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these cells in association with cancer development is corroborated by experimental mouse
models (15, 42), and human (25, 34, 43) studies, indicating that MDSCs develop as a function of
tumor progression. For instance, our group has previously reported that FVBN202 mice, which
overexpress the rat neu oncogene in their mammary glands, develop atypical ductal hyperplasia
(ADH) and ductal carcinoma in situ (DCIS) in mammary epithelial cells prior to the formation of
spontaneous mammary tumors (44). DCIS of the breast is conventionally regarded as a precursor
of invasive breast cancer, and ADH is a risk factor for the development of the disease (45, 46).
Compromised anti-neu immune responses occur as a result of the emergence of such
premalignant events which are characterized by an accumulation of MDSCs in the blood, bone
marrow, secondary lymphoid tissues, and within tumor lesions due to an increased production of
tumor-derived soluble factors (44, 47-51). Such findings provide evidence that MDSCs function
as potent inhibitors of antitumor immunity in breast cancer models. Likewise, human MDSCs
have been observed to negatively regulate both adaptive and innate immunity during cancer
development and progression, with accumulation having been observed in peripheral blood and
lymphoid tissues as well as draining tumor sites of cancer-bearing patients (40). In addition to
breast cancer, the accumulation of MDSCs has been observed in hepatocellular, pancreatic,
esophageal, and colorectal cancers (35).
Thus, MDSC accumulation is paramount in the ability of cancer to evade effective immune
responses; devising strategies to overcome MDSCs is critical to improving effective anti-tumor
immunity.

Modulation of the TME to overcome tumor-induced immune suppression

4

As MDSCs are immature cells of myeloid lineage, one may hypothesize that providing the
correct signal to these cells may support their maturation into cells which may support anti-tumor
function, such as dendritic cells (DCs) or M1 macrophage subsets. Indeed, studies in animal
models suggest that activated NKT cells may have a role in modulating the immunosuppressive
TME by promoting the conversion of MDSCs into DCs (16, 52, 53), yielding enhanced, rather
than suppressed anti-tumor immune responses, while also potentially decreasing the pool of
environmentally induced Tregs (31-33). Our group has recently observed that activated CD25+
NKT cells can promote the maturation of human MDSCs in vitro, which renders them
immunostimulatory in early stage breast cancer patients (54). The physiological role of NKT
cells in tumor immunity is yet to be fully defined, but it appears a primary function of these cells
is to activate DCs to promote antigen-specific T-cell responses (55-57). Furthermore, the ability
of NKT cells to direct myeloid lineage cellular differentiation is becoming apparent. Hedge and
colleagues (58) have demonstrated the ability of NKT cells to induce the differentiation of
monocytes into DCs as a result of secretion of granulocyte–macrophage colony-stimulating
factor and IL-13 and, similarly, others have reported on the ability of innate immune cells to
induce DC maturation (59-61).
NK cells, traditionally considered to function as effector cells in the innate arm of the immune
system, have also recently been shown to play immunoregulatory ‘helper’ functions through an
ability to activate and enhance the ability of DCs to produce proinflammatory cytokines and to
stimulate Th1 and cytotoxic T lymphocyte responses of tumor-specific CD4+ and CD8+ T cells
(62). Furthermore, Wong et al. (63) have recently described an ability of IL-18 primed human
NK cells to promote DC activation and DC-mediated induction of type-1 immune responses
against cancer via a chemokine-dependent mechanism. Similarly, a study by Srivastava et al (64)
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has demonstrated that cetuximab, a chimeric monoclonal antibody that targets the EGF receptor
and is approved for use in colorectal as well as head and neck cancers, also functions to activate
NK cells and support dendritic cell maturation through NKG2D/MICA binding, with subsequent
priming of tumor-antigen specific T cells. Such findings emphasize a role for NK cells
functioning in a ‘helper’ role in which DCs are activated and result in the priming of anti-tumor
T-cell responses.
Much attention in the field of cellular immunotherapy of cancer has recently focused on the use
of genetic engineering of the T cell receptor to improve T cell specificity for MHC class I
restricted tumor antigen peptides (65), or the use of chimeric antigen receptor (CAR) modified T
cells to target MHC-unrestricted native cell surface antigens (66). These approaches, which
consist of a purified T cell product, have had some success in the treatment of hematological
cancer, but have been of limited therapeutic efficacy in the treatment of solid cancer (67-72). The
gold standard for ACT of solid cancer remains the use of tumor-infiltrating lymphocytes (TIL).
TIL are harvested from surgically excised tumor and expanded ex vivo in the presence of IL-2.
This technique was developed by Steven Rosenberg and colleagues in the late 1980s (73, 74),
and has resulted in overall response rates of 48–72% for the treatment of advanced melanoma
(75, 76). It is important to appreciate that the cellular composition of TIL is most certainly
enriched with effector lymphocytes beyond traditional α/ T cells. While CD4+ and CD8+ T cells
do indeed comprise a large percentage of the TIL product, NK cells, NKT cells as well as /δ T
cells have also been detected (77-79). Given the superior responses observed using TIL, rather
than purified T cells in solid cancers (80), such data must lead us to pursue an understanding of
the mechanistic crosstalk among the various lineages of leukocytes in order to manipulate that
communication network to lead to a more effective eradication of tumor cells.
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Therefore, developing a cellular based immunotherapy for cancer which includes T cells as well
as NK and NKT cells will likely lead to the orchestration of more effective activation of DCs and
other APCs which may further promote endogenous T cell responses in addition to the
transferred T cells and may have the benefit of reducing the frequency of MDSCs.

ACT of breast cancer utilizing reprogrammed memory T cells and CD25+ NKT cells
Our group has recently observed that the expression of molecules involved in the activation
signaling of NK cells as well as NK cell:target interactions is increased in breast cancer patients
with a favorable prognosis (81). Additionally, we have demonstrated that immune function genes
involved in the crosstalk between adaptive and innate immune responses were exclusively
upregulated in breast cancer patients with relapse-free survival (82). These finding suggest that
innate immune signals within the TME may function to support adaptive anti-tumor immune
responses.
Therefore, a strategy to enhance the cross-talk between innate and adaptive immune cells is one
of immune cell reprogramming, ex vivo, and infusing these cells as ACT in order to increase the
number of functionally superior tumor-sensitized T cells as well as to induce the activation of
NKT cells to provide signals to modulate myeloid cells in secondary lymphoid tissues and the
TME. Immune cell reprogramming requires activation of antigen experienced immune cells,
followed by phenotypic manipulation using -c cytokines.

Activation of antigen-sensitized T cells: An antigen-independent protocol using Bryostatin
1 and Ionomycin
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Circulating tumor-reactive T cells have been identified in the peripheral blood as well as draining
lymph nodes of cancer patients (83-88) and, therefore, represent a potential source of cells with
endogenous reactivity against tumor-associated antigens (TAAs) for use in ACT. Stimulation of
CD3 and CD28 using beads or monoclonal antibodies without the presence of antigen has been
widely used as a method to induce T-cell activation and expansion, which may then be used for
ACT (89-92). This method, however, leads to nonspecific polyclonal T-cell proliferation, and
depending upon the anatomical location from which the cells were harvested, may lead to
insufficient frequencies of expanded tumor-sensitized T cells for use in ACT. As an alternative
approach, preclinical studies have reported that the combined use of the pharmacological agents
bryostatin 1 and ionomycin (B/I) selectively stimulates tumor-sensitized T cells in vitro, without
requiring the presence of antigen; lymphocytes from sarcoma-bearing mice activated with B/I
and expanded with IL-2 underwent tumor-specific T-cell expansion by orders of magnitude (93).
Bryostatin 1 functions by activating T cells through protein kinase C (PKC) activity (94), which
leads to the secretion of IL-2 and the generation of a proliferative response when combined with
ionomycin (95). Naıve T cells, in contrast to primed T cells, are impaired in TcR downregulation
upon exposure to the classical PKC activator phorbol 12, 13-dibutyrate (96), suggesting PKC
activators may differentially regulate naive and primed T cells. In fact, TcR downregulation has
been attributed to PKC-θ activity in primed T cells (97). Von Essen et al. (96) have demonstrated
that the majority of PKC-θ exists as a high-molecular disulfide-linked inactive form in the
plasma membrane of naıve T cells, whereas primed T cells express an active form of PKC-θ;
activation of PKC-θ is redox dependent and requires de novo synthesis of the major redox
regulator glutathione during T-cell activation. Furthermore, differential localization of PKC-θ
occurs following activation of primed T cells and naıve T cells (98, 99). PKC-θ has also been
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implicated in having a central role in the anti-tumor activity of NK cells (100). Such observations
underscore the ability of PKC activators to elicit distinct TcR signaling in naıve versus primed T
cells. This suggests that the activity of bryostatin 1 preferentially mimics TcR signaling in
primed T cells, theoretically activating T cells with specificity for several different TAAs
expressed within the same tumor, and may stimulate innate immune cells; this results in their
collective activation and subsequent responses to treatment with cytokine cocktails as discussed
below. Importantly, it has been reported that in vivo administration of bryostatin 1 does not result
in high-grade toxicities (101).

Immune cell phenotypic manipulation using the γ-chain cytokines
The selective stimulation of primed T cells and innate immune cells isolated from peripheral
blood or draining lymph nodes with B/I followed by ex vivo culture with homeostatic cytokines
is a potential approach to 'reprogram' lymphocytes to elicit more efficacious anti-tumor immune
responses upon reinfusion during ACT. Lymphocyte homeostasis is mediated in large part by the
activity of -c dependent signaling. The -c cytokines are so named due to their sharing of the
cytokine receptor

chain. The

chain is coupled with cytokine-specific receptor subunits which

then compose the receptor motif. In particular, the -c cytokines, IL-2, IL-7 and IL-15 have been
widely reported to support memory T-cell homeostasis as well as enhancement of NK cell
function and terminal NKT-cell maturation (102-106). Others have previously reported that T
central memory (Tcm) cells are more effective than the T effector phenotype in generating longlasting protection against tumor cells in vivo (107, 108). Importantly, our group has made similar
observations in the FVBN202 mouse model using ACT which contained an enriched component
of Tcm cells that had been reprogrammed using B/I and the -c cytokines IL-2, IL-7 and IL-15
9

protected animals from tumor challenge as well as tumor rechallenge two months later,
demonstrating the functionality of the ex vivo reprogrammed memory T cell response (12, 16,
109).
Importantly, we have previously demonstrated that immune cell activation and phenotypic
reprogramming using B/I and -c cytokines also robustly increased the frequency of CD25+ NKT
cells which rendered T cells resistant to MDSC suppression in in vitro studies in both mouse
models as well as breast cancer patients (16, 54), and induced in vitro maturation of human
MDSCs (54).
These data suggest that signals provided by CD25+ NKT cells may function in the secondary
lymphoid tissue and the TME of tumor-bearing hosts to support adaptive immune responses by
modulating cells of myeloid lineage. We therefore hypothesized that ACT using both Tcm and
CD25+ NKT cells may therefore have therapeutic efficacy against primary breast cancer.

Epigenetic enhancement of tumor immunogenicity: Dec as an in situ vaccine
An additional barrier to successful immunotherapy of breast cancer is the weak immunogenicity
of tumor cells, for example, expression of tumor associated antigens to which the immune
system is tolerant. Therefore, improving the immunogenicity of breast tumor cells is essential to
improving tumor immunotherapy. To this end, in situ induction of foreign-like antigens, such as
cancer testis antigens (CTAs), to which adaptive immunity is not tolerized, is a promising option.
CTAs are highly immunogenic with no natural self-tolerance due to the observation that they are
normally only expressed during embryonic development; after birth, expression is generally
limited to immunologically privileged germ cells and the placenta (110). Aberrant CTA
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expression was first described in melanoma; as such, this expression was found to generate
CTA-specific cytotoxic T-cell responses (111). Recently, it was reported that treatment of
metastatic melanoma with autologous CD4+ T cells specific for the CTA, NY-ESO-1, mediated
a durable clinical remission (112). In addition to melanoma, CTA expression has also been
observed in hematological malignancies (113) as well as solid tumors, including breast cancer
(114, 115). Furthermore, CTA expression in breast cancer has been shown to elicit a broad range
of cellular and humoral immune responses (114, 116, 117); both CD8+ T cell and CD79+ B cell
infiltration has been observed in primary and metastatic NY-ESO-1 expressing breast cancer
(118). Of note, a significantly elevated expression of NY-ESO-1 and MAGE-A was detected in
triple negative breast cancers (119), which therefore represent antigenic targets in an otherwise
perceived immunologically refractory breast cancer subtype.
The expression of CTAs is normally silenced by methylation within the promoter region of these
genes. Methylation at the C-5 position of cytosine bases within DNA is a covalent chemical
modification which characterizes a key, biologically functional, epigenetic modification of the
animal genome (120). This action primarily occurs at CpG dinucleotides in mammals, where
DNA-methyltransferases (DNMTs) mediate the transfer of methyl groups to cytosine, thereby
generating 5-methylcytosine (5mC) that has been shown to play a critical role in cellular protein
expression by transcriptional silencing of genes (121). Aberrant CTA expression likely occurs
due to epigenetic molecular alterations which arise during tumor progression; cancer cells
display drastic changes in DNA methylation status, typically exhibiting global DNA
hypomethylation as well as region-specific hypermethylation (122), resulting in irregular
expression of CTAs.
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While CTAs are an attractive target, the aberrant expression of these proteins within a
heterogeneous tumor may limit the efficacy of any CTA-specific immunotherapy to only those
tumor clones which are CTA-positive. Therefore, in order to induce and/or increase expression
of CTAs to function as target antigens, it is possible to modulate the tumor epigenome to initiate
the cellular CTA transcriptional program; such an approach will serve to impart a more
immunogenic tumor cell phenotype. Aza and Dec are both hypomethylating agents employed in
epigenetic therapy to modify cellular methylation patterns; both of these agents have been
approved for clinical use in the treatment of myelodysplastic syndrome. Aza and Dec function as
cytosine analogs, which lead to their incorporation into newly synthesized DNA strands during S
phase of the cell cycle; these agents have been shown to induce and/or increase the expression of
various CTAs in a variety of in vitro and in vivo tumor models (113, 116-118). Both Aza and
Dec have demonstrated the ability to induce the expression of CTAs, as well as the tumor
suppressor gene p53 (123) and the death receptor Fas (124) on tumor cells. These are attributed
to their capacity to function as potent DNMT inhibitors through the formation of a covalent
complex with a cysteine residue at the active site of DNMT1, which therefore results in CpG
island demethylation during cellular proliferation. This, in turn, results in hypomethylation
within the promoter of tumor suppressor genes as well as highly immunogenic CTAs (120, 125127), thereby rendering tumor cells susceptible to CTA-reactive immune responses and
potentially reducing the proliferative capacity of tumor cells by restoring p53 expression. Others
have demonstrated the feasibility to induce CTA expression in vivo using Dec in the 4T1 model
of murine breast carcinoma, resulting in greater tumor cell cytotoxicity upon treatment with
CTA-specific T cells (128).
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Dec is a particularly attractive option to induce CTA expression as it functions as a prodrug
which requires activation by deoxycytidine kinase (DCK), an enzyme preferentially expressed in
tumor cells and myeloid cells. Thus, the effects of Dec are likely tumor specific, thus protecting
T and B cells from the potentially deleterious demethylating effects of this agent. In addition,
DCK has been found to be overexpressed in poor outcome breast cancer (129), suggesting that
epigenetic therapy to induce CTA expression may prove to be an efficacious approach in breast
cancer patients with poor prognosis.
The aim of Chapter One was to determine the ability of ACT to induce regression of established
breast cancer in the FVBN202 mouse model by utilizing reprogrammed immune cells which
were resistant to MDSCs. Induction of CTAs in these tumors and reprogramming CTAsensitized immune cells was tested to determine the ability of CTA-targeted cellular therapy to
enhance the response to ACT.
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MATERIALS AND METHODS

Mouse model
FVBN202 transgenic female mice (The Jackson Laboratory; Bar Harbor, ME) were used
between 8 and 12 weeks of age throughout these experiments. These mice overexpress nonmutated, non-activated rat neu transgene under the regulation of the mouse mammary tumor
virus promoter (130). These mice develop premalignant mammary hyperplasia similar to ductal
carcinoma in situ prior to the development of spontaneous carcinoma (44). Premalignant events
in FVBN202 mice include the accumulation of endogenous MDSCs (44). These studies have
been reviewed and approved by the Institutional Animal Care and Use Committee at Virginia
Commonwealth University.

Tumor cell lines
The neu overexpressing mouse mammary carcinoma (MMC) cell line was established from a
spontaneous mammary tumor harvested from FVBN202 mice. Tumor cells were maintained in
RPMI 1640 supplemented with 10% FBS.

Ex vivo reprogramming and expansion of splenocytes
FVBN202 transgenic mice were inoculated in the mammary fat pad with 3 × 106 MMC cells.
Tumor growth was monitored by digital caliper, and tumor volumes were calculated by volume
(v) = (L [length] × W [width]2)/2. As previously described (16, 54), splenocytes were harvested
21–β5 days after tumor challenge, when the tumor had reached ≥ 1000mm3. Splenocytes were
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then cultured in complete medium (RPMI 1640 supplemented with 10 % FBS, L-glutamine
(2 mM), 100 U/ml penicillin, and 100 μg/ml Streptomycin) and were stimulated with Bryostatin
1 (2 nM) (Sigma, Saint Louis, MO), Ionomycin (1 μM) (Calbiochem, San Diego, CA), and 80
U/ml of IL-2 (Peprotech) for 16–18 h. Lymphocytes were then washed thrice and cultured at 106
cells/ml in complete medium with IL-7 and IL-15 (20 ng/ml, Peprotech, Rocky Hill, NJ). After
24 h, 20 U/ml of IL-2 was added to the complete medium. The following day, the cells were
washed and cultured at 106 cells/ml in complete medium with 40 U/ml of IL-2. After 48 h, cells
were washed and cultured at 106 cells/ml in complete medium with 40 U/ml of IL-2. Twentyfour hours later, lymphocytes were washed and cultured at 106 cells/ml in complete medium with
40 U/ml of IL-2. Lymphocytes were harvested 24 h later on the sixth day and were then either
used for in vitro studies or in vivo as ACT.

Adoptive cellular therapy
Twenty-four hours prior to ACT, FVBN202 mice were injected i.p. with CYP (100 mg/kg) to
induce lymphopenia. Individual groups of mice were challenged intradermally with 3 x 106
MMC cells. Individual groups of mice then received reprogrammed splenocytes i.v. at a dose of
70 × 106/mouse once the tumor became palpable (50-70mm3) (+ACT), or remained untreated
(Control).

Characterization of splenocytes
Spleens of FVBN202 mice bearing primary tumors that served as donors of ACT were harvested
when the tumor was ≥ 1000mm3, and were then homogenized into a single cell suspension as
previously described (16); splenocytes were then characterized using flow cytometry on day 0,
15

day 1 and day 6 of the expansion and reprogramming procedure. Reagents used for flow
cytometry: anti-CD16/32 Ab (93), FITC-CD3 (17A2); FITC-CD11b (M1/70); PE-GR-1 (RB68C5); PE-CD25 (3C7); Allophycocyanin-CD49b (DX5); Allophycocyanin-CD62L (MEL-14);
PercP/CY5.5-CD4 (GK1.5); PE/CY7-CD8α (5γ-6.7); all of which were purchased from
Biolegend (San Diego, CA). All reagents were used at the manufacture’s recommended
concentration. Cellular staining was performed as previously described by our group (16, 54).
Multicolor data acquisition was performed using a FACSCanto II (BD Biosciences). Data was
analyzed using FCS Express v4.07 (De Novo Software; Glendale, CA).

In vitro and in vivo induction of CTA expression in MMC cells and cDNA synthesis
MMC cells were cultured in the presence of 3µM Dec (Sigma-Aldrich; St. Louis, MO) for 72
hours. Medium was then removed and cells were washed with PBS, and then treated with
TRIzol® (Life Technologies) per the manufacturer’s instructions. In vivo, FVBN202 mice
bearing primary tumor ≥ 1000mm3 were injected with Dec (2.5mg/kg) once daily for five days.
Mice were euthanized and tumors were harvested 3 days later, minced, then treated with
TRIzol® per the manufacturer’s instructions. Contaminate DNA was then removed by Dnase I
digestion from both the in vitro and in vivo specimens; RNA was then purified, followed by
cDNA synthesis as previously described (131).

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) for the detection of CTA
expression
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Quantitative reverse-transcriptase PCR was performed in triplicate wells using SensiMix SYBR
and Fluorescein Kit according to the manufacturer’s procedure (BIOLINE) with the BioRad
CFX96 Real-Time PCR Detection System. qRT-PCR was performed using primers specific for
six murine CTAs and murine GAPDH (Table 1). The reaction was initiated by a denaturing
period of 10 minutes at 95°C, followed by 40 cycles of 95°C for 0:15 minutes, 60°C for 0:30
minutes, and 72C for 0:15 minutes. Relative CTA expression was computed after normalization
to GAPDH using the ΔΔCq method.

IFN-γ ELISA
Splenocytes from FVBN202 mice bearing primary tumors were reprogrammed as described
above. Reprogrammed immune cells were then cultured in complete medium with irradiated
(140Gy) MMC cells or irradiated CTA-expressing MMC (as described above) at a 10:1 ratio for
β0 hours. Supernatants were then collected and stored at −80°C until assayed. IFN- was
detected using a Mouse IFN- ELISA kit (BD Biosciences), according to the manufacturer’s
protocol.

Sample size and power calculation justification for patient CTA expression
The observed gene expression data were transformed into a natural logarithm for normality.
Assume that the actual true difference between the two groups (recurrence vs non-recurrence) in
a gene expression and the actual standard deviation were observed in our preliminary results.
Also assume that the ratio of the size of the two groups is 1:1. Therefore, by a two-sample z test,
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the sample size per group and the total sample size (Table 2) are required to gain at least 80%
power to detect the difference between the two groups at a two-sided significance of 5%.

Clinical specimens
Tissue specimens had been collected from female breast cancer patients and maintained in the
VCU Massey Cancer Center Tissue & Data Acquisition and Analysis Core (TDAAC). Frozen
tissue was used for RNA extraction. These studies have been reviewed and approved by the
Institutional Review Board (HM10920 and 2471-Tissue Acquisition System for Cancer
Research) at Virginia Commonwealth University.

Statistical analysis
Outcomes are summarized by basic descriptive statistics such as mean and standard error of the
mean (SEM); differences between groups are illustrated using graphical data presented as mean
± SEM. Statistical comparisons between groups were made using one-tailed and two-tailed
Student t test per the specific hypothesis. P-value ≤ 0.05 was considered statistically significant.
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RESULTS

ACT utilizing reprogrammed murine splenocytes which are resistant to MDSCs fails to
reject established primary tumors in the FVBN202 mouse
It was demonstrated that tumor-derived factors increase the accumulation of MDSCs (27),
thereby inhibiting the therapeutic efficacy of anti-tumor immune responses. We have previously
established an ex vivo protocol for reprogramming tumor-sensitized immune cells in which
tumor-reactive T cells became resistant to the suppressive functions of MDSCs due to the
activity of CD25+ NKT cells (16, 54). In order to determine if reprogrammed, tumor-sensitized,
immune cells could enhance the anti-tumor efficacy of immunotherapy by overcoming MDSCs,
FVBN202 mice bearing primary tumors received ACT when the tumor had reached 50-70mm3,
or remained untreated. As shown in Figure 1, ACT did not slow the rate of tumor growth (left
panel) or improve overall survival (right panel) in recipient mice compared to untreated control
mice.

Dec induces CTA expression in human breast cancer cells.
Since overcoming MDSCs was not sufficient to enhance therapeutic efficacy of ACT, we sought
to determine whether the immunogenicity of mammary tumor cells can be enhanced by inducing
the expression of CTAs. First, we sought to determine the translational capability of
epigenetically modifying tumor cells to express CTA. To do this, we utilized two human breast
cancer cell lines, MCF-7 and SKBR3, for in vitro treatment with Dec; control cells remained
untreated. We observed a greater than two-fold increase in 4/9 CTA-specific transcripts for both
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cell lines (Figure 2). This observation suggests the use of Dec may have clinical applicability to
induce CTA expression within human breast tumors. We then questioned whether CTA
expression may have a role in protecting breast cancer patients from disease recurrence; the
hypothesis being that CTA expression within the tumor generates robust adaptive immune
responses that may eliminate residual tumor cells after the completion of conventional cancer
therapies. Therefore, CTA expression in primary tumor lesions might have prognostic value. We
performed retrospective studies by using tumor biopsies that were collected from 10 breast
cancer patients at the time of initial therapy, 5 of which had remained relapse free at least 62
months and 5 which had relapsed within 76 months (Table 3). Upon RNA extraction from the
tissue samples, qRT-PCR was performed to determine the trend of CTA expression in patients
who experienced disease relapse, or who had remained relapse free. As shown in Figure 3, five
of the CTAs investigated demonstrated a strong trend toward increased expression in patients
that remained relapse-free, suggesting there may be a positive correlation between increased
CTA expression and survival after initial therapy. Statistically significant p-values were not
achieved, however; this is likely due to the limited sample size of patients available for this
study. Within this limited sample size, patients possessed diverse characteristics in terms of age,
neoadjuvant therapy, tumor stage, hormone receptor and HER-2 status (Table 3). The sample
size required to gain at least 80% power at a two-sided type I error of 5% to detect the difference
in CTA expression between such diverse patients who either relapsed or remained relapse-free is
shown in Table 2; this ideal sample size ranges from 11 patients per group (SLLP1) to 427
patients per group (MAGE A4). Therefore, understanding the role of CTAs in relapse-free
survival will require studying a larger pool of patients and stratifying CTA expression with other
known prognostic factors.
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Dec upregulates CTA expression in primary murine tumor cells in vitro and in vivo, and
reduces the frequency of splenic MDSCs.
Due to the promising results as to clinical translatability of the induction of CTA expression in
human tumor cells (Figures 2 and 3), we began to perform preclinical studies. It was
hypothesized that poor immunogenicity of the tumor allowed tumor progression in the ACT
recipient mice (Figure 1); thus, improving tumor cell immunogenicity may improve the efficacy
of ACT and lead to tumor regression. Therefore, the DNA demethylating agent, Dec, was
utilized to determine if CTA expression could be induced and/or upregulated in MMC cells in
vitro and in a setting of primary disease in vivo. As seen in Figure 4, treatment of MMC cells in
vitro with Dec lead to an observed increase in levels of 3/5 CTA coding transcripts. Additionally,
following five sequential injections of Dec to mice bearing primary MMC tumor all five CTA
genes examined displayed upregulation compared to untreated tumor-bearing mice, with
AKAP4, ESX1 and MAGE A4 increasing expression 10-fold or greater.
Furthermore, we observed that the administration of Dec to primary breast cancer-bearing mice
significantly reduced the frequency of Gr1+CD11b+ MDSCs (Figure 5), suggesting Dec may
have a dual role in enhancing tumor cell immunogenicity while also reducing the frequency of
suppressive myeloid cells.
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Splenocytes harvested from mice bearing CTA-expressing primary tumor demonstrate
expansion and phenotypic characteristics typical of successful reprogramming, and
demonstrate enhanced anti-tumor immune responses in vitro.
Next, we hypothesized that the induction of CTA expression in tumor-bearing mice would
sensitize their splenocytes against these highly immunogenic antigens and therefore may prove
to be superior donors for ACT. Thus, characterization of the ability of CTA-sensitized
splenocytes to expand after B/I stimulation and culture with IL-2, IL7 and IL-15 was performed.
As seen in Figure 6A, the ability of splenocytes harvested from Dec-treated tumor-bearing mice
to expand was similar to that observed from control mice after the six day procedure.
Furthermore, the frequencies of CD4+ and CD8+ T cells as well as the frequencies of CD25+
NK and NKT cells remained comparable on the final day of ex vivo procedure, day 6 (Figures 6B
and 6D). Activated CD25+ NK cells and CD25+ NKT cells were also established one day after
stimulation with B/I and IL-2 (Figure 6D). Importantly, however, significant reductions in CD4+
(40% vs. 70%; p=0.009) and CD8+ (25% vs. 50%; p=0.037) central memory T cells (CD44+
CD62Lhigh) with a reciprocal increase in CD4+ (50% vs. 12%; p=0.004) and CD8+ (60% vs.
35%; p=0.02) effector memory T cells (CD44+ CD62Lint) was observed in mice treated with
Dec, as seen in Figure 6C. Thus, while splenocytes harvested from Dec-treated mice can be
successfully reprogrammed and expanded, the use of such cells for ACT in vivo may limit the
anti-tumor efficacy due to the reduced frequency of central memory T cells.
Next, we sought to determine the ability of such CTA-sensitized and reprogrammed splenocytes
to produce an anti-tumor response in the presence of MMC cells and CTA-expressing MMC
cells. As demonstrated in Figure 7, CTA-expressing MMC cells induced a 2-fold greater release
of IFN- compared to control (p=0.0001). This suggests that reprogrammed CTA-sensitized
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splenocytes for ACT against CTA-expressing primary tumors may generate an enhanced antitumor immune response.
ACT fails to reject CTA positive established primary tumors in FVBN202 mice.
We next studied the effect of utilizing reprogrammed CTA-sensitized splenocytes for ACT of
FVBN202 mice bearing established primary cancer which had been pretreated with Dec to
induce CTA expression. Dec injections began once tumors became palpable and ACT was
performed when tumor had reached 50-70mm3. As seen in Figure 8, ACT used in this manner
did not induce regression of the tumor; the growth kinetics were similar to the control group.
However, the combination of Dec with ACT does appear to extend survival compared with ACT
alone, demonstrated in Figure 1.
Altogether these data suggest that targeting established primary breast cancer using
reprogrammed cellular immunotherapy, even with improved immunogenicity of the tumor and
overcoming MDSCs, cannot produce an objective response. However, targeting CTA-expressing
tumor cells using ACT in a setting of residual disease to prevent distant relapse may be an
effective strategy.
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DISCUSSION
Development of cancer in immunocompetent individuals suggests that the host’s unmodified
immune response fails to protect the host from cancer due to the weak immunogenicity of many
tumor cells. In addition, tumor-derived factors increase MDSCs which in turn dismantle antitumor immune responses, as previously reported by our group and others (15, 27, 28). In order to
overcome such immunosuppressive mechanisms, we have developed a novel method to
reprogram tumor-associated antigen (TAA)-sensitized immune cells, ex vivo, by pharmacologic
activation using Bryostatin 1 and Ionomycin (B/I) and culture with the common gamma chain ( c) cytokines IL-7, IL-15 and IL-2. Reprogrammed immune cells display superior IFNsecretion, an enhanced frequency of highly efficacious central memory T cells (Tcm), as well as
CD25+ NK and CD25+ NKT cells (16). Importantly, these cells establish a cellular crosstalk to
render MDSCs immunostimulatory, rather than immunosuppressive and prevent murine breast
cancer when used in ACT prophylactically (16). We also showed the clinical application of this
reprogramming protocol using PBMC of patients with early stage breast cancer (54). Here, we
sought to determine whether administration of ACT in a therapeutic setting against established
primary tumors could induce tumor regression due to the ability of reprogrammed immune cells
to overcome MDSCs. Contrary to our hypothesis, utilizing reprogrammed immune cells for ACT
did not slow the rate of tumor growth or improve overall survival in FVBN202 mice bearing
established primary MMC. These data suggest that tumors utilize multiple mechanisms which
need to be tackled simultaneously. Therefore, we decided to combine reprogramming of tumorsensitized immune cells with modulation of tumor cells, in situ, in order to improve
tumor/immune cell crosstalk. The former was expected to overcome MDSCs and the latter was
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expected to enhance immunogenicity of tumor cells by inducing the expression of highly
immunogenic CTAs.
To induce the expression of CTAs in MMC, we used a demethylating drug, Dec, in order to
hypomethylate the promoter of these genes and induce their expression (132-136). Therefore,
Dec is expected to enhance immunogenicity of tumor cells. In fact, we showed that Dec was able
to induce CTA expression in MMC as well as in human breast tumor cell lines, in vitro, as
determined by qRT-PCR. The future implementation of additional techniques, such as
immunohistochemistry or fluorescence in situ hybridization would also yield information as to
the ability of Dec to homogenously induce CTA expression throughout the tumor. Treatment of
tumor-bearing mice with Dec also resulted in the induction of CTAs, as determined by qRTPCR, in the tumor as well as the elimination of MDSCs, in vivo. Such CTA expression was
associated with the induction of CTA reactive immune response which produce higher levels of
IFN- against CTA expressing MMC compared with wild type MMC. However, the combined
use of Dec and ACT utilizing reprogrammed immune cells failed to produce objective responses
against established primary MMC. These data suggest that tackling MDSC and enhancing the
immunogenicity of tumor cells simultaneously may not be sufficient to induce objective
responses against well-established breast cancer.
This failure could be associated with downregulation of neu expression in the tumor cells, in
vivo. In addition, cessation of Dec administration could result in the reversion of the methylation
patterns within the CTAs promoter region, consequentially resulting in the reduction or complete
loss of CTAs within the tumor, as we demonstrate in Chapter Three. These data suggest that
overcoming MDSCs and improving tumor cell immunogenicity is not sufficient to enhance the
therapeutic efficacy of ACT, perhaps due to unsustained expression of CTAs and/or tumor
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antigen loss or downregulation under immune pressure. In fact, the effect of anti-tumor immune
responses in editing the tumor has been reported by several groups. For example, IFN- was
shown to promote immunoediting and subsequent tumor escape in the CT26 colon carcinoma by
down-regulation of the expression of gp70 immunogenic tumor antigen (137). Tumor-specific
IFN- was also shown to be essential for successful initial immunotherapy, but it also impaired
subsequent secondary or durable anti-tumor immune responses (138). Farrar et al. (139)
demonstrated that IFN- producing T cells can establish and maintain cancer dormancy; however
the progression of cancer from indolent to aggressive tumors occurred in the presence of
increased expression of IFN- -inducible genes (140). Romieu-Mourez et al. (141) also showed
that treatment of HER-2/neu positive cells with IFN- resulted in the suppression of protective
anti-tumor immune responses. We also reported that immunotherapy of rat neu overexpressing
mouse mammary carcinoma (MMC) elicited neu-specific IFN- producing CD8+ T cells that in
turn facilitated breast cancer recurrence of neu antigen negative variant tumors following initial
rejection of MMC tumor cells in immunocompetent mice (142, 143). The tumor antigen loss was
due to hypermethylation of the neu promoter and loss of neu both at mRNA and protein levels
(142, 144), resulting in escape of the tumor from further neu-specific immune responses. It is
likely that DNA methylation may also impact HER-2/neu gene amplification in humans, as
suggested by others (145). Subsequent studies showed that the tumor editing functions of CD8+
T cells induced epithelial to mesenchymal transition (EMT) of MMC, and as a result induced neu
antigen loss and generated breast cancer stem cells (BCSC)-like tumor clones (144).
In clinical studies, a prospective randomized trial showed that tumor relapse in melanoma
patients who were immunized with NY-ESO-1 vaccine was associated with downregulation of
NY-ESO-1 and HLA class I in their tumor. This suggests immunoediting and escape of the
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tumor under pressure from NY-ESO-1-specific immune responses (146). In patients with ductal
carcinoma in situ (DCIS), HER-2/neu-targeted vaccination induced HER-2/neu-specific IFNproducing T cell responses and resulted in HER-2/neu antigen loss (147). Although the authors
considered this HER-2/neu loss a positive outcome of the immune response, no follow-up studies
have been performed to determine whether patients with HER-2/neu loss in their tumors might
end up with recurrence of more invasive tumors. We reported that patients with HER-2/neu
negative breast cancer had HER-2/neu-specific IFN- producing T cell responses which were
associated with nuclear translocation of IFN- receptor α in the tumor site (86). This suggests
that patients with HER-2/neu negative breast cancer might have had undetectable HER-2/neu
positive premalignant tumors in the past that had lost HER-2/neu expression and progressed to
invasive carcinoma under immune pressure. The fact that 55–75% of patients with premalignant
DCIS overexpress HER-2/neu in their tumor lesions and 75% of breast cancers are HER-2/neu
negative may suggest the progression of HER-2/neu positive DCIS to HER-2/neu negative breast
cancer only in the tumor clones that express variable levels IFN- receptor  (148). This
possibility is also supported by the observation that overexpression of HER-2/neu in DCIS
lesions is usually accompanied by invasive foci (149). In fact, the low frequency of HER-2/neu
expression (20–25%) in invasive breast cancer implies that HER-2/neu loss is an epiphenomenon
of disease progression (150). Evaluation of HER-2/neu expression in tumor lesions of patients
with breast cancer revealed overexpression of HER-2/neu in primary tumors and its loss in
synchronous metastasis (151) as well as gain of HER-2/neu overexpression in metastatic tumors
(152). Such discordance between primary and metastatic tumors in the expression of HER-2/neu
suggests that HER-2/neu loss in vivo may be associated with distant recurrence or metastasis
only in certain tumor clones. In prostate cancer, HER-2/neu positive tumors, DU145 and PC-3,
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that responded to IFN- (likely due to sufficient expression of IFN- receptor α), showed downregulation of HER-2/neu expression whereas another prostate tumor line, LNCaP, that failed to
respond to IFN- did not show any change in the expression of HER-2/neu (153). Such failure of
LNCaP was later shown to be due to the lack of JAK1 gene expression (154).
Despite the presence of pre-existing tumor-specific immune responses, breast cancer patients
often do not benefit from immunotherapy (e.g. vaccines, antibodies). For example, although
Trastuzumab (in combination with chemotherapy) prolongs the survival of women with
advanced HER-2/neu+ breast cancer, the vast majority of women will develop resistance within
one year of treatment initiation and 15% of patients are de novo resistant (155). Similarly, in a
Phase II study by Peoples and colleagues, the benefit of a HER-2/neu peptide vaccine (i.e.
prevention of recurrence) was minimal and non-significant despite the generation of high level
HER-2/neu-specific CD8+ T cell responses (156). Although the reason for the resistance or lack
of benefit is unclear, it could be related to the recent findings of Reim et al. (157), who showed
that Trastuzumab associated with IFN-

producing NK cells expanded tumorigenic

CD44highCD24lowHER-2/neulow BCSC in vitro. We have observed such epigenetic effects of
IFN- during neu antigen loss and tumor relapse in our mouse model of mammary carcinoma
(142). Therefore, levels of IFN- production or levels of the expression of IFN- receptor α on
tumor cells may determine whether a tumor inhibitory or a relapse promoting effect of IFNmay prevail. High levels of IFN- and/or IFN- receptor α expression or the lack of the
expression can induce a robust tumor rejection via IFN- -dependent or -independent mechanisms
whereas intermediate levels of IFN- and/or IFN- receptor α expression may facilitate tumor
escape and relapse (158). This hypothetical model, which is suggested by our recent
observations, may also predict the direction of discordance between primary and metastatic
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breast cancers in the expression of HER-2/neu such that tumor clones with low levels of IFNreceptor α that escaped anti-tumor immune responses may retain HER-2/neu expression during
metastasis.
In conclusion, the application of ACT combined with the blockade of a number of tumor escape
mechanisms could not offer an effective therapeutic strategy against breast cancer because
proliferating tumor cells undergo continuous change during cell division which could dismantle
ACT. In the next chapter we tested anti-tumor efficacy of ACT combined with a demethylating
drug, Aza, against MRD in patients with multiple myeloma after conventional chemotherapy and
autologous stem cell transplantation (ASCT).
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Chapter Two

INTRODUCTION
The results of Chapter One indicate that ACT using reprogrammed immune cells against
established primary breast cancer was not effective, even when combined with Dec
chemotherapy for rendering tumor cells highly immunogenic by the induction of CTA
expression in tumor cells. In retrospect, this was not surprising. Human vaccines and
immunotherapy against infectious diseases are only effective in a prophylactic setting either prior
to exposure to the infectious agents, including pathogen-associated cancers, or during the
incubation period or dormancy after the exposure. Therefore, we sought to determine the
efficacy of immunotherapy against MRD when combined with Aza for the induction of CTA
expression in residual tumor cells in order to prevent disease progression and relapse. In a phase
II randomized clinical trial, patients with multiple myeloma (MM) received autologous
lymphocyte infusion (ALI) in a setting of ASCT, generated to react with CTA-expressing
myeloma cells using Aza and stimulated with the immune-modulatory agent Lenalidomide or
Rev.

Stem cell transplantation following the modulation of tumor-immune crosstalk
Allogeneic stem cell transplantation (allo-SCT) is associated with a reduction in the relapse rate
in patients with multiple myeloma (MM) on the basis of an allo-immune graft vs. myeloma
effect, mediated by donor immune cells targeting tumor (myeloma)-specific antigens, resulting
in prolonged remission. Allografting is, however, complicated by graft-versus-host disease and
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unacceptable treatment-related mortality. On the other hand, patients undergoing high dose
therapy with autologous stem cell transplantation (ASCT) remain at risk for relapse, despite
maintenance and consolidation regimens (159). An alternative strategy is needed to relieve the
burden of treatment toxicity observed in patients with myeloma while also maintaining and
prolonging current treatment efficacy. Immunotherapeutic interventions mimicking graft-versusmyeloma effect in the ASCT setting may provide such an option. However efficacious, safe, and
widely applicable strategies for immunotherapy remain elusive, limiting this option only to a
select number of participants in clinical trials at tertiary cancer centers (160).
Cancer testis antigens (CTA) represent potential targets for immunotherapy in myeloma. These
proteins are highly immunogenic with no natural self-tolerance because, under normal
circumstances, they are only expressed in ‘immunologically privileged’ germ cells, and in the
placenta (110). Aberrant CTA expression has been observed in both solid tumors and in
hematological malignancies, particularly in MM (113). This often elicits a broad range of
cellular and humoral immune responses. In myeloma, several reports have described sporadic
over-expression of CTA and accompanying CTA-specific T cell and B cell responses (161-165).
Induced CTA alloreactivity has also been reported in MM patients undergoing allografting,
possibly associated with relapse-free responses (166). It is noteworthy that CTA expression is
regulated by methylation of CpG islands in the promoters of these genes, which are mostly
located on the X chromosome. There is evidence suggesting that therapy with Aza, a potent
DNA methyl-transferase inhibitor, increases the expression of various CTA in a variety of in
vitro and in vivo tumor models (128, 167, 168).
We hypothesized that in vivo induction of CTA by Aza may induce a CTA-specific T cell
response if it is sequentially administered with Rev, which is widely used in the therapy of MM.
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Rev functions in part by increasing T cell and NK cell tumor cytotoxicity in vitro (169, 170).
Additionally, Rev stimulates T cell proliferation and secretion of interleukin 2 (IL-2) and IFN-
in T cell co-stimulation assays (171, 172), therefore resulting in similar effect rendered by B/I
during the reprogramming procedure described in chapter 1. Further, CTA-specific T cells
generated by this combination of Aza and Rev, when adoptively transferred to ASCT recipients,
could expand in vivo and provide robust protection from disease progression. Additionally, the
alkylating agent, melphalan, has found a distinctive role in autologous stem cell transplantation
(ASCT) and allogeneic stem cell transplantation (allo-SCT), due to its broad antitumor activity,
ability to ablate the bone marrow, and potent immunosuppressive effects (173), and remains the
most common conditioning agent in transplantation for myeloma (174). Melphalan has been
shown to significantly reduce tumor burden in MM patients. As early as 1983, high-dose
melphalan (140 mg/m2) in combination with ASCT led to a complete remission (CR; no
detectable myeloma protein in the bone marrow) in one patient with MM (175). Later, it was
shown in a cohort of 23 patients with refractory myeloma receiving 80-140 mg/m2 of melphalan
that tumor mass was reduced by more than 75% in 14 patients (176). Selby et al. (177) reported
on the use of high-dose melphalan (140 mg/m2) therapy for 58 previously untreated patients with
myeloma. A CR in 27% of the patients was achieved and 51% of the patients entered a partial
response (PR; more than 50% reduction in myeloma protein and improvement in all other
features). Therefore, in the setting of this study, transplant conditioning and ASCT produce both
a state of MRD, as well as lymphodepletion, promoting the preferential proliferation of
adoptively transferred CTA-specific T cells, leading to the promotion of effective adaptive
cellular immunotherapy (160).
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A multi-step phase II study was conducted to determine the feasibility of generating CTAspecific T cells in MM patients and their application in post-transplant maintenance to control
residual disease (NCT01050790). MM patients received sequential Aza and Rev (Aza-Rev) to
induce the expression of immunogenic CTA on malignant plasma cells and elicit a CTA-specific
cellular immune response. The patients had autologous lymphocytes collected and cryopreserved
following the second and third cycle of this regimen. After completion of this investigational
regimen patients underwent stem cell mobilization and eventually ASCT. The autologous
lymphocytes were adoptively transferred to the patients in the second month after transplant.
Here, we demonstrate the feasibility of collecting and reinfusing autologous lymphocytes
following ASCT in a setting of MRD. Further, we show induction of the expression of CTA in
bone marrow of MM patients and an increase in CTA reactive T cells.
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MATERIALS AND METHODS

Patients
Patients were enrolled on a prospective phase II clinical trial approved by the Virginia
Commonwealth University (VCU) Institutional Review Board (MCC12430). MM patients
referred to VCU's bone marrow transplant program had to meet the following eligibility criteria;
presence of residual disease, with either quantifiable serum or urinary M protein or free light
chains, in the presence of a positive immunofixation or clonal bone marrow plasma cells; age
between 18 and 70 years; able to undergo high dose therapy and SCT; adequate performance
status, marrow (absolute neutrophil count of >1·5 × 109/l, platelet count >100 × 109/l) and end
organ function. Patients refractory to or progressing on therapy with lenalidomide were
excluded. Patients with high β-microglobulin (≥0·055 g/l) and adverse cytogenetic changes
were offered tandem SCT, whereas those with standard risk disease underwent a single autograft.
Investigational regimen
Patients with MM who were in a partial remission or plateau phase underwent 3 cycles of
therapy with Aza 75 mg/m2 given subcutaneously from day 1-5 (Vidaza; Celgene Corporation,
Summit, NJ, USA), and Rev 10 mg daily given orally, from day 6-21 (Celgene Corporation).
The 3 cycles of therapy were administered at 4-week intervals prior to blood stem cell
mobilization. No planned corticosteroids were administered during this therapy. Following
3 weeks of therapy in the second and third cycles of Aza-Rev, autologous lymphocytes were
collected by a single, 18-litre lymphapheresis procedure and cryopreserved (Figure 9).
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After completion of the third cycle of Aza-Rev, peripheral blood stem cell mobilization was
performed using granulocyte colony-stimulating factor (G-CSF) 10 μg/kg/day subcutaneously
from day 1 until the end of apheresis, either with or without plerixafor (0.24 mg/kg
subcutaneously from day 4 until the end of apheresis). Patients then went on to receive high dose
melphalan (either 140 or 200 mg/m2) on day -2, and underwent autologous SCT on day 0. GMCSF (5 μg/kg/day) was administered from day 4 post-transplant for hematopoietic engraftment.
Standard antimicrobial prophylaxis was administered.
Autologous lymphocyte infusion (ALI) was performed between day +30 to +60 of the SCT
(following second transplant in tandem SCT recipients), after resolution of regimen-related
toxicities and in the absence of active infections. Autologous lymphocytes collected following
cycles 2 and 3 were infused together (Figure 9). Diphenhydramine and acetaminophen were
administered for infusion reaction prophylaxis. Corticosteroid administration was avoided as
much as possible following SCT and ALI. Patients were not given any routine maintenance
therapy for myeloma following ALI, except for bisphosphonates when indicated. Periodic
myeloma restaging was performed to monitor disease status.

qRT-PCR for the detection of CTA expression
Patient underwent bone marrow aspiration and biopsy before and after investigational therapy for
standard histological studies. qRT-PCR was performed as described above. Both pre- and postAza-Rev treatment bone marrow samples were used to determine the expression of 10 human
CTA transcripts [MAGEA3, MAGEA4, MAGEA5, MAGEA6, MAGEC1, CTAG1B (NY-ESO-1),
SPACA3 (SLLP1), AKAP4, SPA17, SPANXB1 & SPANXB2], using CTA-specific primers and
human GAPDH (Table 4). Initially, qRT-PCR was performed using RNA isolated from
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unfractionated Ficoll-Hypaque separated marrow mononuclear cells. Subsequent patients had
CD138+ cells isolated from marrow mononuclear cells using an EasySep human CD138 positive
selection kit, as instructed by the manufacturer (STEMCELL Technologies, Tukwila, WA, USA)
followed by qRT-PCR analysis of CD138+ plasma cells and CD138- fractions.
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IFN-γ ELISA for the detection of CTA-specific T cell responses
Blood samples, autologous lymphocytes and stem cells from the patients were evaluated for the
presence of T and NK cells, as well as for CTA (NY-ESO-1)-specific T cells, before and after
Aza-Rev therapy and after ASCT. NY-ESO-1 was selected as the antigenic target to be studied
due to its frequent up-regulation in the majority of patients (4/6) following Aza therapy and the
availability of recombinant protein for performing IFN- ELISA, as previously described (16,
86). Briefly, cellular co-cultures were developed in which autologous lymphocytes were cultured
with autologous monocyte-derived DCs (2:1) in the presence or absence of recombinant NYESO-1 (8 μg/ml; γH Biomedical; Uppsala, Sweden). Supernatants were collected after 20 h and
subjected to IFN-ELISA (BD Biosciences, Franklin Lakes, NJ, USA).
Immuno-phenotypic analysis of the blood and stem cell apheresis product for measuring cellular
immune parameters was performed, using a dual-platform technique on a Cytomics™ FC500
flow cytometer (Beckman Coulter Inc., Miami, FL, USA). Antibodies to CD3, CD4, CD8,
CD34, and CD56 (Beckman Coulter, Inc.) were employed to quantify T cell subsets,
haematopoietic stem cells, and NK cells.
Study design
This was a phase II study designed to test the feasibility of safely giving Aza-Rev to patients
with MM, followed by the collection and administration of ALI. The study was designed with
the expectation that ≥70% of the patients would be able to mobilize a cell dose of 107
mononuclear cells/kg and that ≥80% of the patients would be able to receive the ALI following
SCT. The required sample size, n = 19, was based on an independent sample χ2 test with a 0.05
one-sided significance level and 80% power to detect that 70% of the patients would be able to
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mobilize the minimal cell dose against the null hypothesis of 40%, and also to detect that 80% of
the patients will be able to get the infusions post-transplant against the null hypothesis of 50%.
Drop-out was assumed to be 30%. Early stopping criteria for hematopoietic toxicity, were
defined as grade 4 neutropenia or thrombocytopenia lasting beyond 7 days, and for nonhematopoietic toxicity, as any unexpected grade 4 toxicity attributable to the Aza-Rev regimen
or ALI, with >30% incidence deemed unacceptable. Disease progression, while on
investigational therapy, with a progression rate of >30% prior to SCT was also unacceptable as
was the inability of >30% of the patients to proceed onto SCT. Disease response and progression
were as defined by the International Myeloma Working Group (178).
Fourteen subjects have been enrolled to date. Temporal changes in CD3+, CD4+, CD8+ and
CD56+ cell subsets at different time points, as well as differences in CTA expressions before and
after Aza-Rev therapy were tested using the Wilcoxon signed-rank test. All tests were one-sided,
and CTA expression increases were deemed significant for P-values < 0.05. The likelihoods for
observing significant outcomes for study aims 1 and 2 are estimated using Bayes methods (179).
We assigned conservative and pessimistic prior beta distributions for each success rate where the
modes matched the null hypothesized success rates for each aim (40% for aim 1; 50% for aim 2),
and assumed that the accumulated success rates were binomial processes based on n observed
subjects. The predictive probability that we would observe efficacious outcomes for both aims
(>70% mobilization for ALI and stem cells; >80% receive infusion) after observing the
remaining (19–n) patients into the study would then be estimated using beta-binomial
distributions.
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RESULTS

Patient demographics
Between February 2010 and February 2012, 14 patients with a median age of 60 years (range
40–69) were enrolled (Table 5). Nine patients were African American, and seven were female.
International Myeloma Working Group stage at diagnosis was I (n = 2), II (n = 6) and III (n = 6).
Six had chromosomal abnormalities, consistent with high-risk disease. A median of two prior
regimens had been administered (range 1–2) and eight had prior therapy with Rev. A median of
10.6 months had elapsed from diagnosis to start of Aza-Rev therapy and 10 cycles of therapy
administered before study therapy was initiated (Table 5).

Response to Aza-Rev and autologous lymphocyte collection
All 14 patients completed 3 cycles of Aza-Rev and underwent two autologous lymphocyte (AL)
collections. In order to determine if Aza-Rev therapy had a deleterious effect on the number of
autologous T cells, a blood differential was performed. Circulating T cell counts were well
preserved following Aza-Rev therapy (P=0.06) resulting in comparable yield of AL at a median
21 d following cycles 2 and 3 of Aza-Rev, with 0.87 ± 0.38 and 0.82 ± 0.29 x 108 CD3+ cells/kg
(n=14, P=0.20) respectively, with the first and second procedures (Table 6). There was no
significant difference in the circulating T cell subset and NK cell counts between the two cycles
of Aza-Rev therapy (Figure 10A). The circulating CD3+ cell count was significantly increased 2
weeks post-ALI compared with the pre-ALI value (P=0.04), as was the CD8+ cell count
(P=0.02) (Figure 10B). CD4+ and CD56+ cell counts displayed an elevated trend when
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comparing pre-ALI with 2 weeks-post ALI, however these values did not reach statistical
significance (P=0.06).

In vivo induction of CTA expression with Aza-Rev in MM
Quantitative RT-PCR evaluating a panel of 10 human CTAs in unfractionated bone marrow
specimens collected before and after Aza-Rev from four patients demonstrated the induction of
6-8 CTAs in each patient (Figure 11A). In order to identify the cells which were being
modulated to induce expression of CTAs, bone marrow cells from two patients were fractionated
into CD138+ plasma cells (presumably residual tumor cells) and CD138- cells. As shown in
Figure 11B, CD138+ cells were the main source of Aza-induced CTA expression. MAGE A4 and
MAGE A6 were expressed in bone marrow cells of all patients after investigational therapy
(n = 6). Expression of other CTAs included MAGE A3 (3/6), MAGE A5 (4/6), MAGE C1 (3/6),
NY-ESO-1 (4/6), SLLP1 (3/6), SP17 (5/6), AKAP4 (5/6), and SPANXB (1/6). When compared to
before and after therapy, CTA expression was significantly increased in 4 of 10 CTA as follows:
MAGEA4 (P = 0.02), MAGE A6 (P = 0.02), SP17 (P = 0.03) and AKAP4 (P = 0.02). The
increase in MAGE A3 (P = 0.09), MAGE A5 (P = 0.08), MAGE C1 (P = 0.13), NY-ESO-1
(P = 0.07), SLLP1 (P = 0.13) and SPANXB (P = 0.50) expression, however, did not reach
statistical significance.

53

54

55

56

57

CTA-specific T cell response following Aza-Rev therapy
In order to determine whether induction of CTA expression in the bone marrow cells was
immunogenic by inducing CTA-specific T cell responses, peripheral blood mononuclear cells
(PBMCs) of patients were used as source of T cells as well as monocyte-derived DCs. T cells
were then cultured with autologous monocyte-derived DCs in the presence or absence of
recombinant NY-ESO-1, and an antigen-specific IFN- release was determined using IFNELISA. As shown in Figure 12, for Patients 1 and 4, NY-ESO-1-reactive T cells appeared after

the administration of the 1st cycle Aza-Rev and peaked following the 3rd cycle; Patient 2 had a
preexisting NY-ESO-1 specific response which persisted after the 3rd cycle of Aza-Rev.
However, the preexisting NY-ESO-1 specific response observed in Patient 3 markedly
diminished following Aza-Rev therapy. As neither Patient 2 nor Patient 3 demonstrated
expression of NY-ESO-1 before Aza-Rev therapy (Figure 11A), these data suggest aberrant
expression of NY-ESO-1 in the tumor in the past, which established an adaptive memory
response, and was then lost. Similarly, Patient 5 demonstrated an early response to NY-ESO-1,
which declined following the 3rd cycle of Aza-Rev and at 8 weeks post-ALI before increasing at
11 months post-ALI. Interestingly, Patient 4, who displayed a low level of NY-ESO-1 induction
in bone marrow (Figure 11A) also showed a low level of NY-ESO-1-reactive T cell responses,
suggesting that the magnitude of CTA expression is directly correlated with the robustness of the
T cell response. The release of IFN- 11months following ALI, was minimal (Patient 2) or was
undetectable (Patient 4) in two patients who were in CR 1 year after transplantation.
Significantly, these patients recorded further improvement in their response from very good
partial response (VGPR; 90% or greater reduction in serum myeloma protein) to CR at 8 and
10 months following ALI. Patients 1 and 5, however, had a persistent weak NY-ESO-1-reactive
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T cell response 1-year post transplant, in the presence of stable MRD. This response became
undetectable by 15 months post-transplantation (data not shown) and both patients entered CR.

Loss of CTA expression following immunotherapy was associated with disease relapse
To identify potential escape mechanisms from ALI, CTA-expressing bone marrow cells were
monitored pre- and post- Rev/Aza in one patient (Patient 14) whose tumor relapsed at 12-weeks
post ALI. After the 3rd cycle of Aza-Rev, CTA-induction was observed specifically in CD138+
plasma cells (Figure 13A). CTA-expression within CD138+ plasma cells was completely lost at
the time of disease progression (Figure 13B), suggesting transient expression of these antigens
may facilitate escape from immune-mediated elimination and result in disease progression.
However, we were not able to monitor the persistence of CTA expression in the majority of the
patients because they obtained favorable outcomes to date, 8/14 currently in CR or VGPR with a
mean follow up of 30 months (Table 7).
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DISCUSSION
This clinical trial demonstrated the in vivo epigenetic induction of highly immunogenic CTAs in
patients with MM. Induction of CTAs was associated with a subsequent cell-mediated immune
response; such CTA-sensitized lymphocytes were cryopreserved and used later as ALI. This was
accomplished with the administration of a well-tolerated regimen of chemo-immunotherapy. In
order to adequately control disease progression, this immunotherapy was designed in a stem cell
transplant scheme, using ALI to target MRD following ASCT, rather than in a setting of large
tumor-burden.
Presently, the only known curative therapy for patients with MM is allo-SCT. The graft-versusmyeloma effect observed following allografting has been linked to the emergence of tumor
antigen-specific cellular and humoral immune response, particularly following donor lymphocyte
infusion (180, 181). Similarly, antibodies against HY antigens in male recipients of female donor
stem cells have been correlated with relapse-free responses following allo-SCT (182). A guiding
principle in understanding such graft-versus-tumor and graft-versus-host responses is the alloreactivity of donor T cells to ‘non-self’ minor histocompatibility antigens, oligopeptides that
differ between human leucocyte antigen (HLA)-matched donors and recipients (183).
Unfortunately, the recognition of such non-self-antigens also triggers graft-versus-host disease,
which erodes the benefit observed in terms of relapse protection following allografting.
Therefore, if the paradigm of immune recognition of ‘non-self’ can be extended to the
autologous setting combined with an epigenetic modulator for the induction of CTA expression
in tumor cells, one may then observe the graft-versus-tumor benefit without the risk of graftversus-host disease.
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Targeting CTAs hold promise in promoting a graft-versus-tumor-like response in an ASCT
setting. In patients with malignant melanoma, NY-ESO-1 reactive T cells have been isolated and
expanded ex vivo and re-infused into autologous recipients with dramatic responses recorded
(112). Recently, in vitro evidence of CTA overexpression by epigenetic modification and an
adaptive T cell response has been demonstrated against MAGEA4 in patients with Hodgkin
lymphoma treated with Dec (184). Similar findings have been reported with acute myeloid
leukemia and myelodysplasia, where therapy with Aza and valproic acid, has led to the
emergence of cytotoxic T cells reactive to MAGEA1, MAGEA2, MAGEC2 and RAGEA1
peptides over the course of treatment (136). Our finding of CTA up-regulation in bone marrow
and plasma cells from myeloma patients with residual disease treated with Aza-Rev in vivo
corroborates these findings. Evaluation of the expression of a limited panel of CTA showed
over-expression of multiple CTA in each patient tested following therapy with Aza.
Interestingly, two patients (2&3) did not show expression of NY-ESO-1 before Aza-Rev therapy
(Figure 11) but their lymphocytes demonstrated substantial release of IFN- in the presence of
autologous DCs pulsed with recombinant NY-ESO-1 (Figure 12). This suggests that a memory
response had been previously established against this CTA at a time when it was expression, the
expression of which was later lost. When we tested the efficacy of Aza-Rev to upregulate CTA
expression in fractionated marrow cell populations, CTA induction in these patients appeared to
be limited to CD138+ plasma cells, as opposed to normal hematopoietic cells. This may be due to
abnormal regulation or activity of epigenetic modifiers, such as DNA methyltransferase, in
cancer cells. Recently, altered histone methylation with a more open chromatin structure has
been demonstrated in patients with chromosomal translocation (4:14) in myeloma, related to
aberrant multiple myeloma SET domain (MMSET) activity (185). This suggests that malignant

64

myeloma cells may be more sensitive to epigenetic modulation in comparison with normal
hematopoietic cells.
CTA reactivity has been invoked as a possible mechanism for graft-versus-leukemia responses in
allo-SCT recipients (186). We tested NY-ESO-1 reactivity by incubating peripheral blood
lymphocytes with recombinant NY-ESO-1 pulsed autologous DCs. NY-ESO-1-reactive T cells
were observed in 5 patients tested, with reactivity correlating with level of NY-ESO-1 expression
observed post Aza-Rev therapy, and being maintained for 2–11 months following SCT. The
post-transplant maintenance of NY-ESO-1-reactivity was prolonged in one patient (Patient 1)
with high levels of NY-ESO-1 expression and MRD before eventually improving to a CR.
Additionally five other patients (Patients 2, 3, 4, 5 & 9) improved their response from VGPR to
CR in the months following ALI. This suggests ongoing anti-tumor activity in the patient with
prolonged MRD and possible maintenance of NY-ESO-1 (and other CTA) expression in
malignant plasma cells. In the future, phenotypic characterization of patient’s T cells at various
time-points would also aid in determining if CTA-specific responses derived from effector or
memory T cells, which would indirectly indicate the status of the patient’s disease. Although we
only tested the reactivity of autologous lymphocytes against NY-ESO-1, the CTA-specific T cell
response elicited may be polyclonal; targeting several different CTA simultaneously providing
enhanced protective capacity. Likewise, antigen loss as a mechanism of tumor escape will also
need to be monitored by evaluating post-transplant persistence of CTA expression on plasma
cells in bone marrow to determine the durability of this epigenetic modification. We observed
loss of CTA expression which was associated with disease progression in one patient.
Thus, due to our observation in Chapter One that immunotherapy is ineffective in reducing
tumor burden of bulky primary CTA-expressing cancer, the data in this chapter suggest that
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targeting CTA-expressing tumor cells in a setting of MRD may be the best time to utilize cellular
immunotherapy for other cancers, including breast cancer.
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Chapter Three
INTRODUCTION
MDSCs are key cellular suppressors of anti-tumor immune responses in breast cancer patients.
Tumor-derived factors drive the accumulation of MDSCs in the bone marrow, secondary
lymphoid organs and at the site of the tumor, thereby inhibiting the efficacy of cellular
immunotherapy against established tumors. A number of strategies have been used to enhance
immunotherapy of cancer by overcoming MDSCs. These strategies fall into three major
categories which include MDSC deactivation, depletion of MDSCs, or conversion of MDSCs to
APCs. The latter approach identified NKT cells as a key facilitator in promoting MDSC
maturation into mature myeloid cells with anti-tumor immune stimulatory function. Previous
work has demonstrated that a function of invariant NKT cells is to promote the maturation of
cells of myeloid lineage, particularly DCs, as discussed above. Likewise, it was reported very
recently in an animal model of breast cancer metastasis that activated NKT cells decrease the
frequency and immunosuppressive activity of MDSCs in tumor-resected mice (187). Additional
studies have demonstrated that activated NKT cells convert MDSCs into immune-stimulatory
APCs (52, 53). Using peripheral blood mononuclear cells (PBMC) of patients with early stage
breast cancer, we also demonstrated that an optimal frequency of CD25+ NKT cells within
unfractionated reprogrammed immune cells, cultured in the presence of MDSCs, induced the
MDSCs to lose/downregulate CD11b which was associated with HLA-DR upregulation. Such
phenotypic modulation was shown to promote anti-Her-2/neu immune responses, in vitro (54).
Therefore, we suggest that inclusion of CD25+ NKT cells in adoptive cellular therapy will
enhance the anti-tumor efficacy of adoptively transferred T cells by modulating MDSCs to
become immunostimulatory.
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Another barrier to a successful cancer immunotherapy is tumor immunoediting and escape from
immunotherapy, which likely occurs in the event of robust anti-tumor immune responses.
Despite the remarkable recent advances in cancer immunotherapy in prolonging patient survival,
the ability of immunotherapy to treat common carcinomas, which account for majority of all
cancer deaths, remains limited. This raises the question: is reduction of tumor burden and
prolonging patient survival weeks to months an acceptable goal for 21st century cancer
therapeutics, or should we further seek to understand the dynamic interplay between cancer cell
and immune cell in order to offer a cure for cancer patients? The status of the tumor cells
themselves when immunotherapy is employed likely determines the effectiveness of the therapy.
The application of immunotherapy to highly proliferative tumors renders the tumors prone to
immunoediting and subsequent immunological escape during cell division (188). An important
point to consider is that human vaccines against infectious diseases are not effective in a setting
of established disease. The rabies vaccine is an exception; however, it is ineffective as a single
agent or at the onset of clinical illness. A successful history of human vaccines against infectious
diseases suggests that cancer immunotherapy can be effective in a prophylactic setting either
prior to exposure to infectious agents including pathogen-associated cancers, during the
incubation period, or during dormancy after the exposure. For instance, the rabies vaccine can be
used as post-exposure prophylaxis because the incubation period or dormancy for rabies is 1-3
months which provides a window for vaccination. However, it should be combined with antirabies immunoglobulin injections into the wound in order to control the infection and allow the
vaccine to work. Prophylactic cancer vaccines have also been successful. The FDA has approved
two vaccines, Gardasil® and Cervarix®, that protect against HPV infection which is the leading
cause of cervical cancer worldwide (189). HPV infection is also responsible for some vaginal,
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vulvar, anal, penile, and oropharyngeal cancers (190). The FDA has also approved a prophylactic
cancer vaccine against HBV infection, which is a cause of liver cancer. Today, most children in
the United States are vaccinated against HBV shortly after birth (191).
In general, conventional cancer therapies including chemotherapy and radiation therapy (RT),
while inducing cell death in the majority of tumor cells, also promote tumor dormancy (192).
Although these treatment-induced dormant cells become resistant to higher doses of nominal
therapies, they may remain sensitive to immunotherapy during the dormant stage due to their
inability to undergo immunoediting. Additionally, it was reported that the anti-tumor efficacy of
many chemotherapeutic drugs is due to the induction of immunogenic cell death (ICD). ICD in
turn induces anti-tumor immune responses, and may subject dormant tumor cells to persistent
immune surveillance, resulting in the prevention of tumor recurrence (193-196).
In the previous chapter, we demonstrated that the combined use of ACT and a demethylating
drug enhanced immunogenicity of tumor cells by inducing CTA expression, and resulted in
objective responses when administered in a setting of MRD. In this chapter, we sought to
evaluate the efficacy of ACT using reprogrammed T cells and NKT cells against experimental
metastatic mammary carcinoma. First, we tested combined use of ACT and Dec against
experimental metastatic breast cancer in FVBN202 mice, as well as the impact of Dec in tumor
immunoediting and escape. Then, we performed mechanistic studies by using ACT alone
without Dec in order to determine anti-tumor efficacy of ACT as well as its role in modulating
MDSCs to become immune stimulatory APCs, in vivo. Finally, we tested our hypothesis that
targeting dormant, but not highly proliferating, mammary tumor cells might overcome tumor
immunoediting and escape. To this end, we conducted studies in vitro in order to determine
sensitivity of different types of dormant tumor cells, indolent dormancy versus quiescent
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dormancy, to immunoediting and escape. We demonstrate that quiescent, but not indolent,
dormant tumor cells are resistant to immunoediting; thus, they could be the best target for
immunotherapy.

70

MATERIALS AND METHODS

Mouse model
FVBN202 transgenic female mice (The Jackson Laboratory; Bar Harbor, ME) were used
between 8 and 12 weeks of age throughout these experiments. These mice overexpress nonmutated, non-activated rat neu transgene under the regulation of the mouse mammary tumor
virus promoter (130). These mice develop premalignant mammary hyperplasia similar to ductal
carcinoma in situ prior to the development of spontaneous carcinoma (44). Premalignant events
in FVBN202 mice include the accumulation of endogenous MDSCs (44). These studies have
been reviewed and approved by the Institutional Animal Care and Use Committee at Virginia
Commonwealth University.

Tumor cell lines
The neu overexpressing mouse mammary carcinoma (MMC) cell line was established from a
spontaneous mammary tumor harvested from FVBN202 mice. Tumor cells were maintained in
RPMI 1640 supplemented with 10% FBS.

Ex vivo reprogramming and expansion of splenocytes
FVBN202 transgenic mice were inoculated in the mammary fat pad with 3 × 106 MMC cells.
Tumor growth was monitored by digital caliper, and tumor volumes were calculated by volume
(v) = (L [length] × W [width]2)/2. As described previously (16, 54), and above, splenocytes were
harvested 21–β5 days after tumor challenge, when the tumor had reached ≥ 1000mm3.
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Adoptive cellular therapy
Twenty-four hours prior to ACT, FVBN202 mice were injected i.p. with CYP (100 mg/kg) to
induce lymphopenia. Individual groups of mice were challenged intravenously (i.v) with serial
dilutions of MMC cells (3.5 × 105, 1 × 105, or 3.5 x 104). Mice then received reprogrammed
splenocytes i.v. at a dose of 70 × 106/mouse later the same day (+ACT), or remained untreated
(No ACT). The study end-point and euthanasia occurred when the animals were considered
moribund upon losing 10-20% of their initial body weight due to disease progression.

Characterization of splenocytes and tumor-infiltrating leukocytes
Spleens and metastatic tumor lesions of FVBN202 mice were harvested when the animals
became moribund, and were then homogenized into a single cell suspension as described
previously (16) and below; splenocytes were then characterized using flow cytometry. Reagents
used for flow cytometry: anti-CD16/32 Ab (93), FITC-CD3 (17A2); FITC-CD11b (M1/70);
FITC-anti mouse IgG (Poly4053); PE-GR-1 (RB6-8C5); PE-CD11c (N418); PE-F4/80 (BM8);
PE-PD-1 (RMP1-30); PE-CD25 (3C7); PE-Ki-67 (16A8); Allophycocyanin-CD49b (DX5);
Allophycocyanin-CD62L (MEL-14); Allophycocyanin-Annexin V; PercP/CY5.5-CD4 (GK1.5);
Alexa Fluor 647-I-Aq (KH116); PercP/CY5.5-CD86 (GL-1); PercP/CY5.5-Rat IgG2a, k Isotype
Control (RTK2758); PE-Dazzle-CD80 (16-10A1); PE-Dazzle-Armenian Hamster IgG Isotype
Control (HTK888); PE/CY7-CD8α (5γ-6.7); PE/CY7-CD40 (3/23);PE/CY7-Rat IgG2a, k
Isotype Control (RTK2758); Brilliant Violet 421-PD-L1 (10F.9G2); Brilliant Violet 605-CD45
(30-F11); propidium iodide (PI), all of which were purchased from Biolegend (San Diego, CA).
BD Horizon V450-Annexin V and FITC-Fixable Viability Stain (FVS); were purchased from
BD Biosciences (Franklin Lakes, NJ). Anti-rat neu antibody (anti–c-Erb2/c-Neu; 7.16.4), was
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purchased from Calbiochem. All reagents were used at the manufacturer’s recommended
concentration. Cellular staining was performed as previously described by our group (16, 54), or
as recommended by the manufacturer (Ki-67, FVS). Multicolor data acquisition was performed
using a LSRFortessa X-20 (BD Biosciences). Data were analyzed using FCS Express v4.07 (De
Novo Software; Glendale, CA).

Sorting of myeloid cells by FACS
Splenocytes were stained for surface expression of CD11b and Gr-1 as described above. Isolated
cells were gated on the myeloid cell population based on their light scattering properties, thereby
excluding cells of lymphoid origin. CD11b+ Gr1+ MDSCs and CD11b-/lo Gr1- myeloid cells
from the ‘No ACT’ and ‘+ACT’ groups were then sorted into independent populations using a
FACSAria (BD Biosciences) as previously described (54). Purity of sorted cells was consistently
greater than 90%.

IFN-γ ELISA
Splenocytes from the ‘No ACT’ and ‘+ACT’ groups were independently cultured in serum-free
RPMI 1640 in order to enrich for non-adherent cells of lymphoid origin from adherent cells of
myeloid origin. After 2 hours, non-adherent splenocytes were cultured in complete medium with
irradiated MMC cells (140Gy) at a 10:1 ratio, and with or without sorted MDSCs or CD11b-/lo
Gr1- myeloid cells at a 2:1 ratio, for 20 hours. Supernatants were then collected and stored at
−80°C until assayed. IFN- was detected in the supernatant using a Mouse IFN- ELISA kit (BD
Biosciences), according to the manufacturer’s protocol.
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Isolation and characterization of lung metastases
Lungs were harvested from the ‘No ACT’ and ‘+ACT’ groups after animals became moribund.
Metastatic lesions were individually excised from the residual lung tissue, and were then
digested in Trypsin-EDTA (0.25%; Life Technologies) overnight at 4°C. The following day, the
suspension was incubated at 37°C for 30 minutes, followed by tissue homogenization to create a
cellular suspension. The cell suspension was then washed twice with RPMI supplemented with
10% FBS. Residual red blood cells were then lysed using ACK lysing buffer, followed by an
additional wash with RPMI 10% FBS. The cell suspension was then placed in cell culture and
cultured with RPMI 10% FBS. Adherent metastatic tumor cells were then allowed to establish
and proliferate for 10-14 days; they were then characterized for the expression of rat neu and PDL1 using flow cytometry.

Characterization of metastatic tumor-infiltrating leukocytes
Lungs from each group were harvested and metastatic lesions were isolated as described above.
After tissue digestion of the metastatic lesions and red blood cell lysis, 106 cells of the
suspension were placed in flow tubes and stained for surface molecules as described above. All
analysis was performed by gating on viable leukocytes (Annexin V- CD45+), thereby
discriminating out apoptotic cells and tumor cells.

Establishment of in vitro tumor cell dormancy
MMC cells were treated with three daily doses of Adriamycin (Doxorubicin Hydrochloride;
Sigma-Aldrich; St. Louis, MO) (1M/day for 2 hours). Residual, dormant MMC cells remained
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adherent to tissue culture flasks, while the MMC cells susceptible to ADR-therapy became nonadherent and were removed from the culture periodically. Assessment of viability, Ki-67
expression and IFN--induced PD-L1 upregulation by flow cytometry occurred 3 weeks after the
final treatment. Similarly, three daily doses of RT (2Gy/day) were also used to establish dormant
MMC cells. ADR and RT-induced dormant MMC cells were used in the cytotoxicity assay 8
days after the final treatment.

Cytotoxicity assay
Reprogrammed splenocytes were cultured with MMC cells or in vitro established dormant
MMC cells at a 10:1 E:T ratio in complete medium (RPMI 1640 supplemented with 100 U/ml
penicillin, 100 μg/ml streptomycin, 10% FBS, 10 mM L-glutamine) with 20 U/ml IL-2
(PeproTech). To determi76e resistance of dormant tumor cells to conventional therapies, ADRinduced dormant MMC cells were treated with a high dose of ADR (1M for 24hrs), and RTinduced dormant MMC cells were treated with a high dose of RT (18Gy). After 48 hours, MMC
cells were harvested and stained for rat neu (anti–c-Erb2/c-Neu; Calbiochem), Annexin V, and
PI as previously described (16). Flow cytometry was used to analyze the viability of neu+ MMC
cells.

Statistical analysis
Outcomes are summarized by basic descriptive statistics such as mean and standard error of the
mean (SEM); differences between groups are illustrated using graphical data presented as mean
± SEM. Statistical comparisons between groups were made using one-tailed and two-tailed
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Student t test per the specific hypothesis. Time to death in the in vivo survival studies was
calculated from baseline to the date of death (due to weight loss ≥ 10%). Kaplan-Meier curves
and log-rank tests are used to illustrate time to death and to test the difference between each
group. A p-value ≤ 0.05 was considered statistically significant.
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RESULTS
Immunotherapy of metastatic tumor can prolong animal survival but fails to cure cancer
We have previously reported that ACT utilizing reprogrammed T cells/NKT cells in a
prophylactic setting protected animals against primary tumors and recall tumor challenge. This
protection was associated with the presence of memory T cells, and CD25+ NKT cells that
rendered T cells resistant to the suppression by MDSC (197). Similar observations were made
using PBMCs from patients with early stage breast cancer such that the presence of CD25+ NKT
cells resulted in the modulation of CD33+CD11b+HLA-DR- MDSCs toward CD33+CD11b/loHLADR+ myeloid cells which in turn overcome the suppressive function of MDSCs (198).
Here, we sought to determine if ACT utilizing reprogrammed immune cells can protect animals
against experimental metastasis. Due to the promising results obtained from the combined use of
ALI and Aza-Rev in patients with MM, we sought to determine whether the combined use of
ACT and Dec could eliminate experimental metastatic MMC. First, we demonstrated that ACT +
Dec resulted in prolonging the survival of animals compared to the control groups, No-ACT or
Dec alone (Figure 14; p=0.0001 and p=0.037, respectively). The evaluation of metastatic tumor
cells showed that Dec alone facilitated downregulation of the neu antigen on metastatic MMC in
the lung (Figure 15A, MFI: 442 vs. 202) as well as total loss of neu antigen in 36% of tumor
cells compared with control MMC cell line containing a residual 5% of neu negative cells
(Figure 15B). Since Dec induces the expression of CTAs and, therefore, functions as an in situ
vaccination by eliciting endogenous T cell responses, neu loss or downregulation in animals who
received Dec could be due to contribution of endogenous T cell response and Dec. To determine
the contribution of Dec in neu antigen loss or downregulation, we performed in vitro studies by
treatment of MMC with Dec alone where the endogenous immune response did not have any
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contribution. We show that Dec treatment resulted in the downregulation of neu expression, but
did not induce total neu loss (Figure 16, p=0.008). In addition, induction of CTAs in human
tumor cell line by treatment with Dec was found to be transient. The expression of CTAs
induced three days after treatment began was found to be severely diminished after the removal
of Dec from the culture medium and then continuing the culture until day seven (Figure 17).
Therefore, due to the induction of tumor escape mechanisms in highly proliferating MMC by
Dec, such as neu loss/downregulation and inability to stably express CTAs, we moved forward to
test the efficacy of ACT against experimental metastases without the inclusion of Dec.
Splenocytes of animals harboring primary mammary tumor or metastatic MMC in the lung can
be reprogrammed, ex vivo, to generate memory T cells and CD25+ NKT cells (Figure 18).
Recipients of ACT were conditioned by the injection of cyclophosphamide (CYP), and
challenged i.v. with MMC cells. Animals served either as control (No ACT), or received ACT
when proliferating MMC cells were present in the circulation (+ACT). As shown in Figure 19,
ACT prolonged survival of animals regardless of whether the source of donor splenocytes was
from primary tumor-bearing mice or from metastatic tumor-bearing mice. Therefore, we
determined that using donor cells from primary tumor-bearing mice had the potential for more
clinical application, in that lymphocytes from early stage breast cancer patients could be isolated
and cryopreserved before the administration of conventional therapies. Then, in a setting in
which the tumor sufficiently responds to initial therapy, cryopreserved lymphocytes could be
thawed, reprogrammed and infused as ACT in order to target residual tumor cells and prevent
relapse or prolong time-to-relapse. We have previously shown that cryopreserved PBMCs can be
successfully reprogrammed (54).

78

We then challenged mice with a serial dilution of MMC cells to induce experimental metastasis
in order to determine if tumor burden may impact the efficacy of ACT. We demonstrated that
ACT prolonged survival of animals regardless of the dose of tumor challenge, but all mice
succumbed to metastatic tumor in the lung (Figure 20A-C).
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ACT utilizing reprogrammed T cells and CD25+ NKT cells sustains an anti-tumor memory
response, in vivo
In order to determine whether reprogrammed memory T cells were maintained in vivo,
splenocytes of ACT recipients were collected when mice become moribund, and cultured with
MMC tumor cells. As shown in Figure 20D, tumor-reactive IFN- production by endogenous
splenic T cells from the +ACT group was greater than that produced by T cells from the NoACT control group. These results suggest that ACT promotes the retention of long-lived antitumor immune responses, and that the lack of full protection against experimental metastases
was not due to the loss of tumor-reactive immune cells.

ACT shifts splenic myeloid cells from Gr1+CD11b+ MDSCs to Gr1-CD11b-/lo myeloid
cells
We next sought to determine whether the failure of ACT to result in complete elimination of the
tumor was due to the inability of reprogrammed immune cells to modulate and overcome the
suppressive function of MDSCs in vivo. Experimental animals (Figure 20) were sacrificed at the
end of the trial when the ACT and No-ACT groups showed similar tumor burden in the lung
(Figure 21A). ACT resulted in a significant reduction in trafficking of myeloid cells to the spleen
in tumor-bearing animals (p=0.002), but the frequency remained higher than that observed in
naïve mice (p=0.001). Importantly, ACT also reduced the frequency of MDSCs in the splenic
myeloid cell compartment (Figure 21B, p=0.005), but not to the level observed in naïve mice
(p=0.008). A similar trend was observed on total MDSCs (Figure 21B, p=0.0001 and p=0.0009).
Conversely, ACT increased the proportion of Gr1-CD11b-/lo cells in the splenic myeloid cell
compartment (Figure 21B, p=0.004), but remained lower than those in naïve mice (p=0.002).
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Similarly, ACT increased percent total of Gr1-CD11b-/lo cells to a frequency similar to that of
naïve mice, when compared with the No-ACT group (Figure 21B, p=0.056).

ACT modulates the phenotype of Gr1+CD11b+ MDSCs in the spleen
As the frequency of MDSCs appears to be altered upon ACT administration, we sought to further
characterize these cells after ACT. Since the expression of MHC class II (MHCII) on MDSCs is
associated with a contact-dependent mechanism of suppression (199), we sought to determine
the frequency of MHCII expression on MDSCs, in vivo. Interestingly, splenic MDSCs of the
+ACT group displayed elevated expression of MHCII in comparison to the No-ACT group
(Figure 22A, 50% vs. 25%); and was similar to the frequency displayed by naïve mice.
Conversely, splenic MDSCs of the No-ACT group were mainly MHCII- compared with the
+ACT group or naïve mice (Figure 22B, 75% vs. 50%). The percentage of total MHCII+
MDSCs in the spleen of metastatic tumor-bearing mice was higher than that in naïve mice, and it
did not change following ACT (Figure 23A). On the other hand, ACT reduced the total
percentage of MHCII- MDSCs in the spleen (Figure 23B, p=0.029), though they remained
higher than those in naïve mice (p=0.039). Since the total percentage of MHCII+ MDSCs and
MHCII- MDSCs in the spleen remained increased compared with those in naïve mice, we
hypothesized that the ratio of MDSCs to T cells in the spleen may have been altered. Therefore,
we calculated the ratio of MDSCs to T cells because it is known that MDSCs suppress T cells
function at high ratios to T cells (1:1 to 1:3). We found a higher proportion of MDSCs to T cells
in the no-ACT group (1:3) compared to the ACT group (1:9) (Figure 23C, p=0.029), suggesting
the MDSCs remaining after ACT have a reduced capacity to suppress the pool of anti-tumor T
cell responses. The proportion of Gr1-CD11b-/lo myeloid cells to T cells did not change
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following ACT (Figure 23D). Since the total percentage of MHCII+ MDSCs in the spleen did
not change following ACT, we also looked at the expression of co-stimulatory molecules on
these cells. As shown in Figure 23E-G, ACT resulted in a significant downregulation of the
expression of CD80 (Figure 23E, p=0.049) and CD86 (Figure 23F, p=0.033), implying MDSCs
in ACT recipients also may also have a reduced suppressive potential per cell (43, 200).
Expression of CD40 did not change in the ACT group compared with the No-ACT group (Figure
23G).

ACT generated splenic Gr1-CD11b-/lo myeloid cells boost anti-tumor immune responses
We have previously reported that the presence of CD25+ NKT cells in reprogrammed immune
cells induced the conversion of a fraction of MDSCs to CD11b-/lo MHC class II+ myeloid
stimulatory cells, in vitro (54). Here, our in vivo studies also showed that only a fraction of
MDSCs were converted to G1-CD11b-/lo myeloid cells; MDSCs were still present in ACT
group, though at a lower frequency compared to the No-ACT group (Figure 21). In order to
determine the immune stimulatory function of newly converted G1-CD11b-/lo myeloid cells, as
well as the immune suppressive function of the remaining Gr1+CD11b+ MDSCs in the ACT
group, splenic myeloid cells from ACT recipients were sorted into Gr1+CD11b+ and Gr1CD11b-/lo cellular populations, and were then cultured with their own endogenous splenicderived lymphocytes in the presence or absence of MMC cells (Figure 24A). Endogenous
splenic-derived lymphocytes and sorted myeloid cells from the No-ACT group were used as
controls (Figure 24B). ACT generated splenic Gr1-CD11b-/lo myeloid cells boosted the release
of tumor-induced IFN-

from endogenous lymphocytes (Figure β4A, p=0.0γ), whereas

Gr1+CD11b+ MDSCs maintained suppressive function when used at a 1:2 ratio to lymphocytes
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(Figure 24A, p=0.008). Cells derived from the No-ACT control group did not demonstrate
tumor-induced IFN-

release in the presence or absence of sorted splenic Gr1-CD11b-/lo

myeloid cells (Figure 24B). Similar to our in vitro observations from animal studies (16), or
patients with early-stage breast cancer (54), the increased tumor-specific IFN- production by
lymphocytes derived from the +ACT group was associated with a higher frequency of splenic
CD25+ NKT cells in these recipient mice (Figure 24C). The frequency of CD25+ NK cells did
not increase following ACT (data not shown). These results suggest that Gr1-CD11b-/lo myeloid
cells generated by ACT were functionally different from those of the No-ACT group, and that
the activity of CD25+ NKT cells in vivo may render them immunostimulatory. Our previous
studies in vitro showed that Gr1-CD11b-/lo myeloid stimulatory cells were converted from a
fraction of Gr1+CD11b+ MDSCs by CD25+ NKT cells (54).
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ACT generated splenic Gr1-CD11b-/lo myeloid cells are unique immune stimulatory cells,
which differ from conventional APCs
Since Gr1-CD11b-/lo myeloid cells generated by ACT showed immune stimulatory function
(Figure 24), and had a higher frequency in contrast with the No-ACT group (Figure 21B), we
next sought to characterize these cells phenotypically. As shown in Figure 25A, frequency of
MHCII expressed by CD11b-/loGr1- myeloid cells in the +ACT group and in naïve mice was
higher than that in the no-ACT group. Gr1-CD11b-/loMHCII+ myeloid cells in the +ACT group
and naïve mice also showed an increased MFI of the co-stimulatory molecule, CD86, compared
with the No-ACT group (Figure 25B). In addition, the +ACT group downregulated the costimulatory molecules, CD40 and CD80, on Gr1-CD11b-/loMHCII+ myeloid cells compared
with naïve mice (Figure 25C, p=0.0002 and p=0.012, respectively) and the no-ACT group
(Figure 25D, p=0.053 and p=0.016, respectively).
In order to determine whether Gr1-CD11b-/loMHCII+ myeloid cells responded to toll-like
receptor (TLR) stimulation and resulted in their maturation,

as has been described for

conventional APCs (201-203), these cells were stimulated with the TLR-4 agonist,
lipopolysaccharide (LPS), in vitro. We used splenocytes from the No ACT group as source of
Gr1-CD11b-/loMHCII+ myeloid cells because they expressed lower levels of MHCII and CD86
expression at baseline. As can be seen in Figure 26, LPS induced the maturation of Gr1-CD11b/loMHCII+ myeloid cells by upregulating the expression of MHCII (MFI: 2000 vs. 5500;
p=0.007), as well as the co-stimulatory molecules CD86 (MFI: 37 vs. 150; p=0.002), CD40
(MFI: 580 vs. 925; p=0.009), and CD80 (MFI: 50 vs. 100; p=0.03).
Since ACT generated Gr1-CD11b-/lo immune stimulatory myeloid

cells displayed

characteristics of APCs by expressing signal I (MHCII) and signal II (CD86), and these cells
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demonstrated maturation patterns generally observed in APCs upon LPS stimulation, we sought
to determine whether these cells were conventional APCs. As shown in Figure 27, nearly all
Gr1-CD11b-/loMHCII+ myeloid cells lacked expression of the DC marker CD11c (Figure 27,
94-97%). The frequency of these myeloid stimulatory cells did not change during tumor
challenge or ACT, accounting for 3-4% of total splenocytes (Figure 27). In addition, these
myeloid stimulatory cells did not express the pan marker of macrophages, F4/80 (Figure 28, 9598%).

Immunotherapy induces tumor escape in proliferating tumor cells and indolent dormant
cells, but not in quiescent dormant cells
Since tumor-reactive lymphocytes persisted following ACT, and modulation of myeloid cells
occurred by reducing MDSCs and increasing myeloid stimulatory cells, we sought to determine
whether tumor immunoediting resulted in the escape of tumor cells from elimination by ACT,
and ultimately death of the animal. Metastatic tumor lesions were isolated from the lung at the
end of the trial and analyzed for the expression of the tumor antigen, neu, and programmed death
ligand 1 (PD-L1). The tumor lesions isolated from +ACT group showed downregulation of the
neu antigen on the tumor cells compared with control MMC tumor cell line and the lesions
isolated from the no-ACT group (Figure 29A, left panel; p=0.00003 and p=0.0008, respectively).
Additionally, 25% of MMC cells isolated from metastatic tumor lesions demonstrated total loss
of neu expression compared with control MMC tumor cell line and the lesions isolated from the
No ACT group (Figure 29A, right panel; p=0.002 and p=0.01, respectively). This suggests that
metastatic MMC cells may escape detection from neu-specific cellular immunity. Additionally,
we detected an upregulation of PD-L1 on the lung metastatic tumor cells compared with control
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MMC tumor cell line (Figure 29B; MFI 390 vs. 78, p=0.00002). Interestingly, the No ACT
group had higher expression of PD-L1 in the tumor compared with the ACT group (MFI 1360
vs. 390, p=0.011). The immune suppressive function of PD-L1 requires engagement with
programmed death receptor 1 (PD-1), which renders immune cells tolerogenic (204, 205).
Importantly, 40-50% of reprogrammed T cells and NKT cells that were used for ACT expressed
PD-1 (Figure 30), but only CD8+ T cells were observed to upregulate PD-1 as a result of
reprogramming (Figure 30; p=0.01). Therefore, we also analyzed tumor-infiltrating T cells for
PD-1 expression, to determine the potential for the PD-1/PD-L1 axis to mediate T cell tolerance
within the tumor site. Interestingly, as seen in Figure 31A, tumor infiltration of CD8+ T cells
was greater in mice receiving ACT compared to untreated mice (14% vs. 3% respectively;
p=0.02). However, expression of PD-1 remained intact on tumor infiltrating CD8 + T (Figure
31B). We did not observe CD4+ T cell infiltration into the tumor lesions (data not shown).
Splenic T cells and NKT cells that were isolated from the +ACT and No-ACT group when
animals became moribund also expressed PD-1, though there was no statistical difference
between the groups (Figure 32, 10% of T cells and 50% of NKT cells). All together, these data
suggest that although ACT promotes the infiltration of CD8+ T cells, the highly proliferative
nature of the metastatic tumors may evade such anti-tumor immune responses by emerging with
reduced expression of the tumor antigen, neu, and upregulating the co-inhibitory molecule PDL1. Thus, we then began to question if residual tumor cells that remain after conventional
cytotoxic therapy, which are generally dormant, also employ similar escape mechanisms or if
they were perhaps more sensitive to immune-mediated elimination.
To determine whether dormant tumor cells were resistant to escape and immunoediting, MMC
tumor cells were treated with ADR in order to establish tumor dormancy. A clinically relevant
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proliferation marker, Ki67, along with a viability dye (FVS), were used to detect viable, indolent
tumor cells (Ki67+/FVS-) and quiescent tumor cells (Ki67-/FVS-). As shown in Figure 33A,
ADR induced apoptosis in the majority of MMC cells; 3 weeks after treatment the number of
FVS- viable MMC cells was reduced from 77% to 31% (p=0.005). The remaining residual viable
tumor cells that escaped chemotherapy-induced apoptosis entered a dormant state, as there was
no significant increase in the number of tumor cells between one week and three weeks after the
completion of ADR chemotherapy (Figure 33B). To determine if dormant tumor cells could
exploit immune escape mechanisms, we treated dormant MMC cells with IFN- , a cytokine
produced and secreted by inflammatory cells in the tumor microenvironment, three weeks after
the completion of ADR treatment in order to provoke PD-L1 expression (206, 207). We
evaluated the expression of PD-L1 on viable proliferating control MMC cells, without
(Untreated) and with IFN-

treatment (Untreated -> IFN- ), as well as on viable dormant tumor

cells without (+ADR) and with IFN-

treatment (+ADR -> IFN- ). ADR or ADR -> IFN-

treatment increased Ki67- quiescent tumor dormancy (Figure 34A, left panel, p=0.02 and
p=0.001, respectively), and reduced the frequency of Ki67+ indolent MMC cells (Figure 34A,
right panel, p=0.02 and p=0.001, respectively). IFN- treatment induced upregulation of PD-L1
on Ki67+ proliferating MMC (Figure 34B, left panel, p=0.002) and Ki67+ indolent tumor cells
(Figure 34B, left panel, p=0.01). Interestingly, Ki67- control MMC cells and Ki67- quiescent
MMC cells did not upregulate PD-L1 (Figure 34B, right panel). As Adriamycin significantly
increases the population of quiescent MMC cells which are less responsive to an inflammatory
environment which may upregulate the expression of PD-L1 compared with indolent dormant
cells or proliferating cells, this suggests that immunotherapy applied after conventional cytotoxic
therapy may be more effective in eliminating Ki-67- tumor cells generated by chemotherapy.
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Dormant MMC cells established by ADR become resistant to chemotherapy, but remain
sensitive to immunotherapy
In order to determine whether dormant MMC cells established by ADR chemotherapy remain
sensitive to immunotherapy, dormancy was established by treating cells with three daily doses of
ADR treatment (1 uM/day for 2 hrs) (Figure 35A); eight days after the final treatment, MMC
cells received a high dose of ADR (1uM for 24 hrs), or were cultured with reprogrammed
immune cells for 48 hrs. ADR treatment induced apoptosis in MMC cells (Figure 35B, p=0.01).
Tumor cells that survived apoptosis became chemo-refractory; additional ADR treatment at a
higher dose (1uM for 24 hrs) did not induce cell death (Figure 35B, average 40% vs. 54%).
However, they remained sensitive to tumor-reactive lymphocytes. In the presence of tumorreactive immune cells, the frequency of viable ADR-treated dormant MMC dropped from 40%
to 8% (Figure 35B, p=0.003). In fact, immunotherapy was more effective than a high dose of
chemotherapy in inducing apoptosis in dormant MMC (Figure 35B, p=0.02). We also established
dormant MMC by three daily doses of RT (2Gy/day); again surviving dormant cells became
refractory to RT. An additional RT at a higher dose (18 Gy) did not markedly decrease the
frequency of viable tumor cells (Figure 36, 53% vs. 52%). However, RT-refractory MMC cells
remained sensitive to tumor-reactive lymphocytes as the viability dropped from 53% to 8%
(Figure 36, p=0.002). In fact, immunotherapy was more effective than a high dose RT on
inducing apoptosis in dormant MMC (Figure 36, p=0.01).
In order to determine the efficacy of targeting dormant tumor cell in vivo, we performed a
preliminary study in which we treated experimental animals bearing primary MMC with ADR,
followed by ACT once the tumor growth plateaued, which represents tumor dormancy. As seen
in Figure 37, both animals treated with ADR exhibited suppression of tumor growth.
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Importantly, the animal which also received ACT exhibited demonstrable tumor regression by
day 24. This data suggests that MMC cells which are in a dormant state can be targeted more
effectively than highly proliferative tumor cells, in vivo.
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DISCUSSION
We developed an experimental metastatic mouse model by i.v. injection of highly proliferative
MMC cells to FVBN202 mice. Animals in this model became moribund within 20-40 days, and
presented with lung metastases upon macroscopic inspection. This model represents the onset of
advanced stage disease. We demonstrated that concurrent use of Dec with ACT using
reprogrammed NKT and T cells prolonged survival of the experimental animals, but failed to
eliminate the tumor as all mice eventually succumbed to metastatic disease in the lung. Failure in
tumor elimination was associated with downregulation of the tumor antigen, neu, on metastatic
tumor cells. Neu downregulation occurred in the presence of Dec, in vitro, whereas total neu loss
and downregulation were evident in the presence of Dec treatment, in vivo. Additionally, in vitro
studies demonstrated that Dec-induced CTA expression was transient; tumor cells quickly
downregulated expression of CTA transcripts upon the cessation of Dec treatment. These data
suggest that Dec may function as an in situ vaccination by inducing immune responses against
the tumor which in turn facilitate total antigen loss. Additional studies involving ACT without
Dec treatment confirmed that total neu antigen loss was mediated by anti-tumor immune
responses, in vivo, whereas our in vitro studies demonstrated that Dec alone only had the
capacity to induce downregulation of neu antigen.
ACT without Dec also prolonged animal survival but, again, it failed to eliminate the tumor as
animals eventually succumbed to metastatic disease in the lung. The data suggest that this was
due to the induction of tumor escape mechanisms by these highly proliferative tumor cells,
including upregulation of PD-L1 and loss of neu antigen by the tumor, which may result from
immunoediting due to the increased infiltration of CD8+ T cells in these tumors. Very
importantly, we identified and characterized novel APCs that were established from a portion of
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MDSCs resulting from the administration of ACT containing CD25+ NKT cells, in vivo. These
novel Gr1-CD11b-/lo immunostimulatory cells displayed a phenotype distinct from conventional
APCs, specifically DCs and macrophages. Finally, promising results in patients with MM
(Chapter Two) were obtained when ACT was administered during a setting of MRD, likely when
indolent and/or quiescent tumor cells were present. Therefore, we hypothesized that targeting
indolent, but not highly proliferating, mammary tumor cells might overcome tumor
immunoediting and escape. Therefore, we conducted studies in order to determine the sensitivity
of different types of dormant cells, indolent dormancy versus quiescent dormancy, to
immunoediting and escape. Our in vitro studies demonstrated that quiescent, but not indolent,
dormant tumor cells are resistant to immunoediting; thus, they may represent the ideal target for
immunotherapy.
We have previously reported that PBMCs collected from patients with early stage breast cancer
can be reprogrammed and expanded ex vivo (54). Here, we compared two different sources of
tumor-sensitized immune cells, including animals harboring early stage primary tumor or those
harboring metastatic tumor in the lung. We demonstrated that immune cells from both sources
can be reprogrammed and expanded ex vivo. ACT utilizing these reprogrammed immune cells
produced similar objective responses. We demonstrated that failure of ACT in complete
elimination of the tumor was not due to the status of metastatic tumor burden, loss of tumorreactive T cells, or the presence of MDSCs. In fact, ACT facilitated modulation of myeloid cells
by inducing a shift from MDSCs toward immune-stimulatory myeloid cells, resulting in a ratio
of MDSCs to T cells below the optimal suppressive level. However, highly proliferative tumor
cells were sensitive to immunoediting due to the activity of ACT. The escape mechanisms
induced by ACT included the induction of PD-L1 and loss of neu antigen on metastatic tumor
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cells. A higher expression of PD-L1 in the no-ACT group compared with the ACT group
suggests that endogenous innate immune response may be involved in the upregulation of PD-L1
on tumor cells. It was reported that innate IFN- is essential for upregulation of PD-L1
expression (207). Intriguingly, an adaptive immune response following ACT reduced PD-L1
expression on tumor cells compared with the no-ACT group, though it was still significantly
higher than MMC tumor prior to challenge. This is important because reprogrammed T cells and
NKT cells that were used for ACT expressed PD-1, and PD-1 expression was sustained after
ACT. However, reprogrammed T cells also produce perforin and granzyme B (16) allowing
them to induce apoptosis in tumor cells before they begin to upregulate PD-L1 mediated by IFN. IFN- produced by reprogrammed T cells increases the level of PD-L1 expression compared
with control MMC. Therefore, prolonged survival in the ACT group could be associated with
lower expression of PD-L1 in MMC compared with no-ACT group, though animals succumbed
to metastatic tumor, as their tumors begin to undergo antigen loss by downregulating the
expression of neu. Therefore, our data suggest that tumors utilize numerous mechanisms to
change during cell division and escape from immunotherapy. These mechanisms were shown to
overcome tumor immune surveillance and reduce the efficacy of immunotherapy (142, 144, 148,
208). On the other hand, dormant tumor cells which were established by chemotherapy or RT
became chemo-resistant or RT-resistant but remained sensitive to immunotherapy. Our findings
are consistent with the reports on the efficacy of ACT in patients with metastatic melanoma
utilizing tumor-infiltrating lymphocytes (TIL) grown in IL-2. ACT utilizing IL-2 expanded TIL
resulted in tumor regression in 49% of patients (209). When ACT was combined with total body
irradiation (TBI) objective responses increased to 72%. Among treated groups, 20% had
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complete tumor regression and over 10 years relapse-free survival (76). Thus far, of the 34
complete responders in the NCI trials, one has recurred (210).
Dormant tumor cells contain Ki67+ indolent cells and Ki67- quiescent cells. Indolent tumor cells
are still capable of proliferating, but represent balanced cellular proliferation and death; therefore
they generally remain dormant. Thus, due to their proliferative nature, they remained sensitive to
immunoediting and escape. On the contrary, Ki67- quiescent dormant cells displayed a reduced
potential for immunoediting; they failed to upregulate PD-L1 in the presence of IFN-
stimulation. Our data suggest that administration of immunotherapy after the completion of
conventional cancer therapies, when tumor dormancy is established, could effectively target
dormant tumor cells. The challenge, however, is to develop a combinatorial chemotherapeutic
strategy which predominantly establishes quiescent dormancy so that tumors are incapable of
escape from subsequent immunotherapy.
Recently, there have been dramatic advances in the field of cancer immunotherapy. However,
these advances have been limited to increasing patients’ survival for a limited period of time
rather than offering a cure for cancer patients. For instance, Sipuleucel-T (Provenge) has
extended survival of patients with metastatic prostate cancer by a median of 4.1 months (211).
Blockade of immune checkpoint molecules has also prolonged survival in patients with advanced
cancer. For instance, anti-CTLA-4 antibody (Ipilimumab) therapy resulted in a 3.5-month gain in
overall survival in patients with stage III or IV metastatic cutaneous melanoma (212).
Cumulative response rates for anti-PD-1 antibody therapy among patients with non-small-cell
lung cancer, melanoma, and renal-cell cancer were 18%, 28%, and 27%, respectively. Responses
were durable such that 20 of 31 responses lasted 1 year or more in patients with 1 year or more
of follow-up (213). On the other hand, administration of immunotherapy in prophylactic settings
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has been successful against many infectious diseases, as well as against HPV-associated cervical
cancer. In addition, the application of stem cell transplantation and donor-derived lymphocyte
infusion is successful only against MRD rather than against active and advanced stage disease.
Therefore, it is reasonable to expect that administration of immunotherapy during MRD or tumor
dormancy could prevent distant recurrence of breast cancer, thereby eliminating mortality
associated with the advanced stages of the disease.
We also demonstrated that ACT utilizing reprogrammed T cells and CD25+ NKT cells resulted
in the modulation of Gr1+CD11b+ MDSCs toward Gr1-CD11b-/lo immune stimulatory myeloid
cells. These findings support our previous in vitro observations as well as the observations by
other groups showing that NKT cells can convert MDSCs to APCs (16, 52-54, 187). We have
previously reported that Gr1+CD11b+ MDSCs became immune stimulatory cells in the presence
of NKT cells; fractionated reprogrammed T cells alone resulted in the failure of ACT in
protecting animals from MMC tumor challenge (16). Here, we showed that conversion of
MDSCs to Gr1-CD11b-/lo immune stimulatory myeloid cells takes place only in a fraction all of
MDSCs. The remaining MDSCs persisted in their suppressive function, in vitro. Importantly,
however, the proportion of T cells to MDSCs, in vivo, was found to be below the optimal
suppressive ratio. It is yet to be determined if Gr1-CD11b-/lo immune stimulatory myeloid cells
are predominantly converted from granulocytic or monocytic MDSCs. We have reported that
MDSCs in MMC-bearing animals are mainly composed of the granulocytic phenotype, though
only monocytic MDSCs were found to be able to suppress T cell responses (27). Therefore, if
granulocytic MDSCs are converted to Gr1-CD11b-/lo immune stimulatory cells, they could
dominate monocytic MDSCs. This could explain why the remaining MDSCs from the ACT
group retained their immune suppressive function in the absence of newly converted Gr1-
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CD11b-/lo immune stimulatory cells. However, the presence of newly converted immune
stimulatory myeloid cells results in the failure of MDSCs to sufficiently suppress anti-tumor T
cells, in vitro (16, 54). This could also explain the multifaceted function of monocytic versus
granulocytic MDSCs in the exacerbation and amelioration of different diseases associated with
the suppression or induction of specific types of the immune response. We have suggested that
the term myeloid regulatory cells (Mregs) can better explain the functions of MDSCs which
contain both monocytic and granulocytic phenotypes (214). In fact, we propose that MDSCs are
a phenotype of Mregs which cannot be converted to immune stimulatory myeloid cells in a
setting of cancer. In addition, controversial reports on the role of these cells in autoimmune
diseases can be consolidated and understood in the context of their regulatory function under
certain conditions, which is not merely limited to immune suppressive function of Gr1+CD11b+
Mregs. The newly converted immune stimulatory myeloid cells of the ACT group showed
CD11bcharacteristics of APCs by expressing MHC class II as well as co-stimulatory molecules.
However, they differed from conventional DCs or macrophages. The Gr1-CD11b-/loMHCII+
immune stimulatory cells that were established following ACT were also phenotypically
different from those in tumor-bearing control mice, i.e., they differed in the expression of MHC
class II and co-stimulatory molecules. The newly converted Gr1-CD11b-/lo myeloid cells were
also functionally different from those in tumor-bearing control mice, as only those from the ACT
group showed immune stimulatory function. These data suggest that ACT by using CD25+ NKT
cells and T cells could act as in situ vaccine by converting a fraction of MDSCs to a unique APC
which require further characterization.
In conclusion, we demonstrate that ACT can prolong survival of animals harboring an active
disease. Our data suggest that ACT could cure breast cancer if it is administered during tumor
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dormancy rather than during the active state of the disease. We also identified a new type of Gr1CD11b-/lo immune stimulatory myeloid cell that were converted from Gr1+CD11b+ MDSCs,
and which differed from conventional APCs. Future work to characterize the phenotype,
function, and development of these cells could lead to strategies to harness the natural
accumulation of MDSCs in cancer patients in order to promote their conversion to myeloid
stimulatory cells which could lead to a more effective generation of endogenous anti-tumor
immune responses.
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Conclusions
The overall results of this work suggest that currently available clinically translatable
immunotherapeutic strategies for the treatment of breast cancer may be best implemented to
function as a relapse prophylaxis, and provides insights into the potential to reprogram the tumor
microenvironment to support anti-tumor immune function.
In Chapter One, we evaluated the efficacy of treating established primary mammary carcinoma
in the FVBN202 mouse with ACT utilizing reprogrammed immune cells, as developed by our
group. We found this strategy to be ineffective in eliminating or inducing regression of primary
mammary carcinoma, even after inducing the expression of highly immunogenic CTAs within
the tumor. This suggests that established breast cancer may not represent the optimal target to
which our immunotherapeutic strategy of ACT may be effective. In Chapter Two, we
participated in a Phase II randomized clinical trial using Aza combined with an
immunomodulator Rev and ACT in patients with multiple myeloma who harbored MRD. We
demonstrated that Aza-Rev induced the expression of a panel of CTAs specifically within
plasma cells harbored in the bone marrow. Such induction of CTA expression generated NYESO-1-specific lymphocytes which were collected and later reinfused into patients as a cellular
therapy after chemotherapy and ASCT, in order to target residual malignant cells and prevent
disease recurrence. This strategy was effective in generating objective responses for patients with
residual multiple myeloma. Therefore, in Chapter Three we demonstrated that ACT using
reprogrammed NKT cells and T cells combined with modulation of tumor using Dec is effective
in prolonging survival of animals harboring early advanced experimental metastatic mammary
carcinoma. However, this treatment failed to eliminate the tumor because of the induction of
tumor immunoediting and escape which is characterized by neu antigen loss/downregulation and
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upregulation of PD-L1 in tumor cells. Importantly, dividing tumor cells were sensitive to
immunoediting whereas quiescent dormant cells were resistant to immunoediting and escape. We
also demonstrated the striking effect of ACT utilizing reprogrammed T and NKT cells to
modulate the splenic myeloid cell compartment, resulting in a reduction in the frequency of
splenic MDSCs while also stimulating the generation of a novel phenotype of immune
stimulatory cell, which functioned to enhance endogenous anti-tumor function in vitro.
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Future Perspective
The results of this work suggest that utilizing ACT containing reprogrammed T cells and NKT
cells may yield the most effective responses when used in a setting of minimal residual disease,
during a period of dormancy after the implementation of conventional therapies. Future studies
should investigate the ability of conventional therapeutics to induce quiescent dormancy, which
is resistant to immunoediting and escape, followed by the administration of immunotherapy in
order to prevent advanced stage disease.
Furthermore, our work suggests the ACT actively functions to modulate splenic myeloid cells to
generate cells capable of promoting anti-tumor immune responses. Additional studies are
required to determine if such ACT-generated Gr1-CD11b-/lo myeloid stimulatory cells possess
antigen presentation capacity, as well as if they can be categorized into a cell lineage by
characterization of the expression of common granulocytic or monocytic proteins, such as Ly6G
and Ly6C, respectively. Also, it will be prudent to determine if such immune stimulatory cells
are directly generated from MDSCs, or arise from an independent progenitor. Such information
may prove to be essential in the development of our knowledge of the methods by which
developing tumors usurp myelopoiesis, and may therefore generate novel strategies by which
one may reestablish the ‘normal’ myelopoietic program to generate myeloid cells with immune
stimulatory properties to further enhance the immune response against breast, and perhaps other
solid tumors.
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Project Title: Cancer Immunotherapy: Reprogramming tumor-immune cellular crosstalk
Funded Years: 2014-2015

Awards/Honors
1. The American Association of Immunologists - 2015 AAI Trainee Abstract Award
Abstract Title: Adoptive Cellular Therapy containing T cells and CD25+ NKT cells
modulates myeloid cells and stimulates endogenous anti-tumor immune function
2. St. Jude Children’s Research Hospital – Postdoctoral Recruitment-2014
3. The Ohio State University – Selected to attend the 2014 Postdoctoral Recruitment Event
4. Virginia Commonwealth University - Nominated to attend the 64th Lindau Nobel
Laureate Meeting - 2014
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5. Adaptive Biotechnologies Corporation - Young Investigator Award
Project Title: Molecular signatures of T cell-mediated tumor rejection: the application of
high throughput sequencing for immunomonitoring of cancer therapy
Awarded: August 2012
6. Virginia Commonwealth University Graduate Student Travel Award
Project Title: Immunotherapy of cancer: re-programming tumor-immune crosstalk
Awarded: October 2012
7. Virginia Commonwealth University Graduate Student Travel Award
Project Title: Sequential common gamma-chain cytokines facilitate differentiation of
tumor-reactive T cells that are resistant to MDSC and can induce rejection of breast
tumors. Awarded: April 2011

Professional Society Membership & Service
 Society for Immunotherapy of Cancer –Student Member (2011-present)


Early Career Scientist Committee Member (2014-present)


Co-chair 2014 Annual Meeting Professional Development Session

 The American Association of Immunologists – Trainee Member (2014-present)
 American Association for Cancer Research – Associate Member (2010-present)
 International Society for Translational Medicine – Member (2011-present)
 American Association of University Professors – Member (2014-present)
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Manuscript Reviews



Pathology – Research and Practice (2015)

Teaching Experience
1. Virginia Commonwealth University – School of Medicine - Richmond, Virginia


Invited Instructor - MICR 686; Advanced Immunology – Spring Semester, 2015
Topic: Crosstalk between NK/NKT cells and MDSC can rescue T cells from
suppression

2. Virginia Commonwealth University – School of Medicine - Richmond, Virginia


Invited Instructor - MICR 686; Advanced Immunology – Spring Semester, 2014
Topic: Ex vivo reprogramming of human T cells for adoptive immunotherapy of
cancer

3. Virginia Commonwealth University – School of Medicine - Richmond, Virginia


Invited Instructor - MICR 686; Advanced Immunology – Spring Semester, 2013
Topic: Crosstalk between NK/NKT cells and MDSC can rescue T cells from
suppression

4. Virginia Commonwealth University – School of Medicine - Richmond, Virginia


Invited Instructor - MICR 686; Advanced Immunology – Spring Semester, 2012
Topic: Epigenetic modulation as an immunotherapeutic approach in cancer

5. Virginia Commonwealth University – School of Dentistry - Richmond, Virginia
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Graduate Teaching Assistant – MICR 513; Infection and Immunity – Fall
Semester, 2011

6. Indiana University – Department of Biology - Bloomington, Indiana


Undergraduate Teaching Instructor – Biological Mechanisms – Spring and Fall
Semester, 2004

Community Service


Higher Achievement – Richmond, Virginia; 2013-2015

Peer-Reviewed Publications
1. Manjili MH, Payne KK. (2015). Prospects in cancer immunotherapy: treating advanced
stage disease or preventing tumor recurrence? Discovery Medicine. 19(107):427-31.
[Review].
2. Payne KK, Bear HD, Manjili MH. (2014). Adoptive cellular therapy of cancer: exploring
innate and adaptive cellular crosstalk to improve anti-tumor efficacy. Future Oncol. 10(10):
1779-94. [Review].
3. Kmieciak M, Payne KK, Wang XY, Manjili MH. (2013). IFN- R is a key determinant of
CD8+ T cell-mediated tumor elimination or tumor escape and relapse in the FVB mouse.
PLoS One. 8:12, e82544
4. Gowda M, Payne KK, Godder K, Manjili MH. (2013). HLA-DR expression on myeloid
cells can be a potential prognostic factor in patients with high risk Neuroblastoma.
Oncoimmunology. 2:10, e26616
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5. Payne KK, Zoon CK, Wan W, Marlar K, Borelli CA, Keim RC, Kenari MN, Kazim AL,
Bear HD, Manjili MH. (2013). Peripheral blood mononuclear cells of patients with breast
cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloidderived suppressor cells. Breast Cancer Res Treat. 142(1):45-57
6. Ascierto ML, Idowu MO, Zhao Y, Khalak H, Payne KK, Wang XY, Dumur CI, Bedognetti
D, Tomei S, Ascierto PA, Shanker A, Bear HD, Wang E, Marincola FM, De Maria A,
Manjili MH. (2013). Molecular signatures mostly associated with NK cells are predictive of
relapse free survival in breast cancer patients. J Transl Med. 11:145.
7. Meier JM, Roberts C, Avent K, Hazlett AF, Berrie J, Payne KK, Hamm D, Chung HM,
Desmarais C, Hogan KT, Archer KJ, Manjili MH, Toor AA. (2013). Fractal Organization of
the Human T Cell Repertoire in Health and Following Stem Cell Transplantation. Biol Blood
Marrow Transplant. 19(3):366-77
8. Payne KK, Toor AA, Wang XY, Manjili MH. (2012). Immunotherapy of cancer: reprogramming tumor-immune crosstalk. Clin Dev Immunol. 2012:760965 [Review]
9. Payne KK, Manjili MH. (2012). Adaptive immune responses associated with breast cancer
relapse. Arch. Immunol. Ther. Exp. 60:345–350 [Review]
10. Toor AA, Payne KK, Chung HM, Hazlett AF, Sabo RT, Clark WB, Kmieciak M, Anderson
J, Buskey A, Roseff S, Williams DC, Roberts C, McCarty J, Manjili MH (2012). Epigenetic
Induction of Adaptive Immune Response in Multiple Myeloma: Sequential Aza and
Lenalidomide to Generate Cancer Testis Antigen Specific Cellular Immunity. Br J Haematol.
158(6):700-11
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11. Manjili MH, Payne KK. (2012). Cancer immunotherapy: re-programming cells of the innate
and adaptive immune systems. Oncoimmunology, 1:2, 201-204 [Review]
12. Kmieciak M*, Basu D*, Payne KK*, Toor A, Yacoub A, Graham L, Sale L, Bear HD,
Manjili MH. (2011). Activated NK T cells and NK cells render T cells resistant to MDSC
and result in an effective adoptive cellular therapy against breast cancer in the FVBN202
transgenic mouse. J Immunol, 187; 708-717 *Authors Contributed Equally
13. Kmieciak M, Payne KK, Idowu MO, Grimes MM, Graham L, Ascierto ML, Wang E, Bear
HD, Manjili MH. (2011). Tumor escape and progression of HER-2/neu negative breast
cancer under immune pressure. J Transl Med, 9:35
14. Sumpter TL, Payne KK, Wilkes DS. (2008). Regulation of the NFAT pathway discriminates
CD4+CD25+ regulatory T cells from CD4+CD25- helper T cells. J Leukoc Bio, 83: 708717.
15. Smith GN, Mickler EA, Payne KK, Lee J, Duncan M, Reynolds J, Foresman B, Wilkes DS.
(2007). Lung transplant metalloproteinase levels are elevated prior to bronchiolitis obliterans
syndrome. Am J Transplant, 7(7):1856-61.

Extramural Presentations
1. Payne KK, Graham L, Bear HD, Manjili MH. (2015). Adoptive Cellular Therapy containing
T cells and CD25+ NKT cells modulates myeloid cells and stimulates endogenous anti-tumor
immune function. [Oral Presentation]. Presented at: IMMUNOLOGY 2015™, Annual
Meeting of The American Association of Immunologists, May 8-12, The American
Association of Immunologists, Inc., New Orleans, Abstract VAC7P.1038
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2. Payne KK. (2014). Cancer immunotherapy: Reprogramming tumor/immune cellular
crosstalk to improve anti-tumor efficacy. [Oral Presentation] Presented at St. Jude Children’s
Research Hospital; Postdoctoral Candidate Seminar, Memphis Tennessee; December 16,
2014.
3. Payne KK. (2014). Reprogramming tumor-immune crosstalk for the immunotherapy of
cancer. [Oral Presentation] Presented at The Ohio State University; 2014 Postdoctoral
Recruitment Event, Columbus Ohio; October 2, 2014.
4. Payne KK, Graham L, Bear HD, Manjili MH. (2014). Cancer immunotherapy: treatment of
established breast cancer or prevention of tumor relapse and metastasis? [abstract] Presented
at: IMMUNOLOGY 2014™, Annual Meeting of The American Association of Immunologists,
May 2-6, The American Association of Immunologists, Inc., Pittsburgh, Abstract 71.27
5. Payne KK, Zoon CK, Wan W, Marlar K, Borelli CA, Keim RC, Kenari MN, Kazim AL,
Bear HD, Manjili MH. (2013) Peripheral blood mononuclear cells of patients with breast
cancer can be reprogrammed to enhance HER-2/neu reactivity and overcome myeloidderived suppressor cells. [abstract] SITC 28th Annual Meeting, National Harbor, Maryland;
November 7-10. Abstract number 191.
6. Meier J, Scalora A, Avent K, Berrie J, Payne KK, Hamm D, Desmarais C, Sanders C,
Hogan KT, Grant S, Archer K, Manjili MH, Roberts CH, Toor AA (2012). Fractal
Organization of the Human T Cell Repertoire in Health and Following Stem Cell
Transplantation. [abstract] 54th ASH Annual Meeting and Exposition, Atlanta, Georgia;
December 8-11.
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7. Payne KK, Roberts C, Sabo R, Chung H, Clark W, McCarty J, Manjili MH, Toor AA.
(2012). Aza for induction of adaptive immunity in multiple myeloma. [abstract] 2nd
International Workshop on The Biology, Prevention, and Treatment of Relapse After
Hematopoietic Stem Cell Transplantation. National Institutes of Health, Bethesda, Maryland;
November 5-6.
8. Payne KK, Hall CE, Toor AA, Bear HD, Wang XY, Manjili MH. (2012). Immunotherapy of
cancer: re-programming tumor-immune crosstalk. [abstract] SITC 27th Annual Meeting,
Bethesda, Maryland; October 24-28. Abstract number 18.
9. Toor AA, Payne KK, Chung HM, Roberts CH, Sabo RT, Kmieciak M, Clark W,
McLaughlin C, Buskey A, Anderson J, Manjili RH, Roseff SD, McCarty JH, Manjili MH.
(2011). Adoptive Immunotherapy In Multiple Myeloma: Epigenetic Modification and
Immunomodulation by Sequential Aza and Lenalidomide to Generate Cancer Testis Antigen
Specific Cellular Immune Responses. [abstract] 53rd ASH Annual Meeting and Exposition,
San Diego, California; December 10-13.
10. Payne KK, Toor AA, Manjili MH. (2011) Cancer Testis Antigens as prognostic biomarkers
for breast cancer patients. [abstract] SITC 26th Annual Meeting, Bethesda, Maryland;
November 4-6.
11. Ascierto ML, Payne KK, Kmieciak M, Idowu MO, Dumur C, Bedognetti D, De Maria A,
Wang E, Marincola FM, Manjili, MH. (2011). Role of NK and NKT cells in Breast Cancer
Patients: association with favorable prognosis. [abstract]

SITC 26th Annual Meeting,

Bethesda, Maryland; November 4-6.
12. Payne KK, Kmieciak M, Basu D, Ramakrishnan V, Bear H, Manjili M (2011). Sequential
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common gamma-chain cytokines facilitate differentiation of tumor-reactive T cells that are
resistant to MDSC and can induce rejection of breast tumors. [abstract] In: Proceedings of
the 102nd Annual Meeting of the American Association for Cancer Research; Apr 2-6;
Orlando, Florida. Philadelphia (PA): AACR; 2011. Abstract number 775.

Intramural Presentations
1. Payne KK. Cancer Immunotherapy: Reprogramming Tumor/Immune Cellular Crosstalk to
Improve Anti-Tumor Efficacy. [Oral Presentation] Final Defense. VCU Department of
Microbiology and Immunology, School of Medicine; July 9, 2015
2. Payne KK, Graham L, Bear HD, Manjili MH. (2015). Adoptive Cellular Therapy containing
T cells and CD25+ NKT cells modulates myeloid cells and stimulates endogenous anti-tumor
immune function. [abstract] VCU Massey Cancer Center Research Retreat, May 22, 2015
3. Payne KK, Graham L, Bear HD, Manjili MH. (2015). Adoptive Cellular Therapy containing
T cells and CD25+ NKT cells modulates myeloid cells and stimulates endogenous anti-tumor
immune function. [Abstract] 11th Annual VCU Women’s Health Research Day, April β, β015
4. Sappal S, Payne KK, Wan W, Idowu M, Dumur CI, Manjili MH. Cancer Testis Antigen
Expression Effect on Breast Cancer Recurrence. [abstract] Medical Student Honors Day,
VCU School of Medicine, May 1, 2015
5. Wallace MM, Payne KK, Keim RC, Dumur CI, Manjili MH. Molecular pathways of breast
cancer dormancy and relapse. [abstract] Medical Student Honors Day, VCU School of
Medicine, May 1, 2015
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6. Payne KK. Re-programming of tumor-immune crosstalk for the immunotherapy of breast
cancer. [Seminar Speaker] VCU Department of Microbiology and Immunology Seminar,
November 21, 2013
7. Payne KK, Zoon CK, Wan W, Marlar K, Borelli CA, Keim RC, Kenari MN, Kazim AL,
Bear HD, Manjili MH. Peripheral blood mononuclear cells of patients with breast cancer can
be reprogrammed to enhance HER-2/neu reactivity and overcome myeloid-derived
suppressor cells. [abstract] VCU Massey Cancer Center Research Retreat, June 13, 2013
8. Payne KK, Kmieciak M, Wang XY, Manjili MH. IFNT cell-mediated tumor elimination or tumor escape and relapse. [abstract] VCU Massey
Cancer Center Research Retreat, June 13, 2013
9. Saleem SJ, Martin RK, Zellner HB, Dean LM, Ngyen K, Payne KK, Bear HD, Manjili MH,
Irani AM, Conrad DH. Mast Cell-histamine release promotes (is required) for the activity of
monocytic myeloid derived suppressor cells. [abstract] VCU Massey Cancer Center Research
Retreat, June 13, 2013
10. Payne KK. Epigenetic modulation of tumor and immune cell re-programming as a
therapeutic approach against cancer. [Seminar Speaker] VCU Department of Microbiology
and Immunology Seminar, November 29, 2012
11. Payne KK, Hall CE, Toor AA, Bear HD, Wang XY, Manjili MH. (2012). Immunotherapy of
cancer: re-programming tumor-immune crosstalk. [abstract] VCU Massey Cancer Center
Research Retreat, October 18, 2012
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12. Payne KK, Zoon C, Graham L, Borrelli C, Detwiler M, Wan W, Kazim L, Bear HD, Manjili
MH. Reprogramming of tumor-sensitized immune cells for immunotherapy of breast cancer.
[Seminar Speaker] VCU Breast Cancer Research Interest Group, August 2, 2012.
13. Payne KK. Epigenetic modulation of tumor and immune cell re-programming as a
therapeutic approach against cancer. [Seminar Speaker] VCU Department of Microbiology
and Immunology Seminar, January 19, 2012
14. Payne KK. In situ vaccination to overcome tumor escape and relapse. [Seminar Speaker]
VCU Breast Cancer Research Interest Group, July 7, 2011
15. Reed T, Payne KK, Kmieciak M, Knutson KL, Dumur CI, Manjili MH, Hartman, MCT.
(2011) Discovery of a cell surface marker for early detection of tumor escape and relapse of
breast cancer. [abstract] VCU Massey Cancer Center Research Retreat, November 7, 2011
16. Payne KK, Toor AA, Manjili MH. (2011) Cancer Testis Antigens as prognostic biomarkers
for breast cancer patients. [abstract] VCU Massey Cancer Center Research Retreat,
November 7, 2011
17. Payne KK, Roberts CH, Hazlett A, Alesi E, Kmieciak M, Sabo RT, Clark W, Manjili RH,
McCarty JM, Chung HM, Toor AA, Manjili MH. (2011) Epigenetic Modifications Induce
Adaptive Immunity: Generation of Cancer Testis Antigen specific cellular immune responses
in multiple myeloma patients. [abstract] VCU Massey Cancer Center Research Retreat,
November 7, 2011
18. Payne KK, Toor AA, Manjili MH. (2011) Cancer Testis Antigens as prognostic biomarkers
for breast cancer patients. [abstract] Virginia Commonwealth University; Watts Research
Poster Symposium, October 18-19, 2011
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19. Payne KK, Kmieciak M, Basu D, Ramakrishnan V, Bear H, Manjili M (2011). Sequential
common gamma chain cytokines can expand cells of the adaptive and innate immune
systems that can overcome myeloid-derived suppressor cells and provide long-term memory
against breast cancer upon adoptive cellular therapy. [Abstract] 7th Annual VCU Women’s
Health Research Day, April 28, 2011
20. Payne KK, Kmieciak M, Basu D, Ramakrishnan V, Bear H, Manjili M (2010). Sequential
common gamma-chain cytokines facilitate differentiation of tumor-reactive T cells that are
resistant to MDSC and can induce rejection of breast tumors. [abstract] Virginia
Commonwealth University Massey Cancer Center Research Retreat, October 15, 2010
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